1
|
Gualandro DM, Puelacher C, Chew MS, Andersson H, Lurati Buse G, Glarner N, Mueller D, Cardozo FAM, Burri K, Mork C, Wussler D, Bolliger D, Osswald S, Caramelli B, Mueller C. Acute heart failure after non-cardiac surgery: incidence, phenotypes, determinants and outcomes. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Primary acute heart failure (AHF) is an established and common cause of hospitalization. AHF may also develop secondarily, e.g. postoperatively (pAHF). Little is known about pAHF.
Purpose
To assess the incidence, phenotypes, determinants and outcomes of pAHF following non-cardiac surgery.
Methods
We prospectively included 9,164 consecutive patients at high cardiovascular risk undergoing 11,262 non-cardiac surgeries. The incidence, phenotypes, determinants and outcome of pAHF, centrally adjudicated by independent cardiologists, was determined. Logistic regression models identified the risk factors for pAHF. Cox regression analysis compared mortality and AHF readmission within 1 year in patients with and without pAHF. External validation was performed using a prospective cohort multicenter study of 1250 patients.
Results
The incidence of pAHF was 2.5% (95% confidence interval [CI] 2.2–2.8%). pAHF most often occurred on postoperative day 2 (median day 4). About half of pAHF (51%) occurred in patients without known HF (de novo pAHF), and 49% in patients with chronic HF. Preserved left ventricular ejection fraction (LVEF) was the dominant phenotype among de novo pAHF (72%), while reduced LVEF was dominant among pAHF in chronic HF (43%). Age, coronary artery disease, peripheral artery disease, diabetes, urgent/emergent surgery, chronic HF, atrial fibrillation, chronic obstructive pulmonary disease, anemia, and chronic myocardial injury were independent predictors of pAHF. Patients with pAHF had significantly higher all-cause mortality (44% vs. 11%, p<0.001) and AHF readmission (15% vs. 2%, p<0.001) within 1 year than patients without pAHF. pAHF was an independent predictor of all-cause mortality (adjusted hazard ratio [aHR] 1.7 [95% CI 1.3–2.2]; P<0.001) and AHF readmission (aHR 2.7 [95% CI 1.7–4.2]; P<0.001) within 1 year. Findings were confirmed in an external validation cohort of 1250 patients, e.g. incidence of pAHF 2.4% (95% CI, 1.6–3.3%).
Conclusions
pAHF frequent developed following non-cardiac surgery, being de novo in about half of cases, and associated with an unacceptable high mortality. Strategies focusing on early detection and treatment of pAHF seem warranted.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Swiss National Science FoundationSwiss Heart Foundation
Collapse
Affiliation(s)
| | - C Puelacher
- University Hospital Basel , Basel , Switzerland
| | - M S Chew
- Linköping University , Linköping , Sweden
| | | | - G Lurati Buse
- University Hospital Düsseldorf , Düsseldorf , Germany
| | - N Glarner
- University Hospital Basel , Basel , Switzerland
| | - D Mueller
- University Hospital Basel , Basel , Switzerland
| | - F A M Cardozo
- Heart Institute (InCor), University of São Paulo Medical School, Cardiology , São Paulo , Brazil
| | - K Burri
- University Hospital Basel , Basel , Switzerland
| | - C Mork
- University Hospital Basel , Basel , Switzerland
| | - D Wussler
- University Hospital Basel , Basel , Switzerland
| | - D Bolliger
- University Hospital Basel , Basel , Switzerland
| | - S Osswald
- University Hospital Basel , Basel , Switzerland
| | - B Caramelli
- Heart Institute (InCor), University of São Paulo Medical School, Cardiology , São Paulo , Brazil
| | - C Mueller
- University Hospital Basel , Basel , Switzerland
| |
Collapse
|
2
|
Ziswiler T, Luciani M, Vanetta C, Springer A, Diteepeng T, Von Eckardstein A, Mueller D, Barbagallo M, Conen D, Rodondi N, Moschovitis G, Osswald S, Kuehne M, Bonati LH, Beer JH. Trimethylamine N-oxide is associated with impaired cognitive function in patients with atrial fibrillation. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Since patients with atrial fibrillation (AF) are predisposed to suffer from major adverse cerebrovascular events (MACE), they are more likely to suffer MACE linked sequelae, such as cognitive impairment. We hypothesised that the gut microbiome derivate trimethylamine N-oxide (TMAO) may amplify this pathomechanism given its hypercoagulative, proinflammatory and proatherogenic effects.
Methods
Patients of the Swiss-AF cohort with determined TMAO plasma levels, cognitive scores (n=2'379) and cerebral magnetic resonance imaging (cMRI) (n=1'722) collected at baseline were included. TMAO levels were measured by liquid chromatography-mass spectrometry (HPLC). Overall cognitive performance was evaluated using the Cognitive Construct (CoCo) score reflecting different cognitive functions measured by four validated neuropsychological assessments, namely the Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT parts A and B), Semantic Fluency Test (SFT) and Digital Symbol Substitution Test (DSST). The scores were compared with the quartiles of patients' TMAO plasma levels (Q1: 0.6–4, Q2: 4–5.8, Q3: 5.8–9.1, Q4: 9.1–164μmol/l) in linear effect models. All models were adjusted for multiple covariates correlating with this association: For TMAO (overall meat consumption >3 times per week, physical activity, glomerular filtration rate, presence of diabetes mellitus), cognitive function (EQ-5D-5L score, geriatric depression scale, education level) and cerebral affects (white matter lesions volume and total brain volume in cMRI). The relevance of high TMAO plasma levels in different stroke groups in cMRI (i.e., clinically overt, silent, or no stroke) were analysed in a subgroup analysis. The subgroups were additionally adjusted for total brain volume to eliminate the effect of simultaneous decrease of cerebral white matter.
Results
After multivariable adjustment, AF patients in the highest quartile of TMAO levels performed significantly poorer in the global cognitive score (CoCo: estimate −0.11, 95% CI [−0.17, −0.05], p=0.002) compared to patients in the lowest quartile. This was observed also in the MoCA, SFT, DSST, TMT-A and TMT-B.
In the subgroup analysis, an association between the highest TMAO quartile (compared with the lowest quartile) and lower CoCo score was found in the group of patients with overt strokes (−0.18, 95% CI [−0.33, −0.04], p=0.012). Weak evidence of the same association was found in the group of patients with silent strokes (−0.13, 95% CI [−0.25, 0.002], p=0.053) and patients with no strokes (−0.08, 95% CI [−0.16, 0.01], p=0.07).
After adjustment for decreased brain volume, the association remained for silent strokes (−0.14, 95% CI [−0.28, −0.01], p=0.036) indicating the impact of TMAO in this subgroup.
Conclusion
TMAO plasma levels were associated with cognitive impairment in patients with AF. Longitudinal data will clarify dynamics and likely causality between TMAO and cognitive impairment.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Swiss National Science Foundation
Collapse
Affiliation(s)
- T Ziswiler
- Cantonal Hospital of Baden, Department of General Internal Medicine , Baden , Switzerland
| | - M Luciani
- Cantonal Hospital of Baden, Department of General Internal Medicine , Baden , Switzerland
| | - C Vanetta
- Swiss Federal Institute of Technology Zurich (ETH Zurich), Seminar for Statistics , Zurich , Switzerland
| | - A Springer
- University Hospital Basel, Cardiovascular Research Institute Basel and Cardiology Division , Basel , Switzerland
| | - T Diteepeng
- University of Zurich, Center for Molecular Cardiology , Schlieren , Switzerland
| | - A Von Eckardstein
- University Hospital Zurich, Institute of Clinical Chemistry , Zurich , Switzerland
| | - D Mueller
- University Hospital Zurich, Institute of Clinical Chemistry , Zurich , Switzerland
| | - M Barbagallo
- University Hospital Zurich, Department of Neurology , Zurich , Switzerland
| | - D Conen
- McMaster University, Population Health Research Institute , Hamilton , Canada
| | - N Rodondi
- University of Bern, Department of General Internal Medicine and Institute of Primary Health Care (BIHAM) , Bern , Switzerland
| | - G Moschovitis
- EOC Cantonal Hospital, Division of Cardiology , Lugano , Switzerland
| | - S Osswald
- University Hospital Basel, Cardiovascular Research Institute Basel and Cardiology Division , Basel , Switzerland
| | - M Kuehne
- University Hospital Basel, Cardiovascular Research Institute Basel and Cardiology Division , Basel , Switzerland
| | - L H Bonati
- University Hospital Basel, Department of Neurology and Stroke Center , Basel , Switzerland
| | - J H Beer
- Cantonal Hospital of Baden, Department of General Internal Medicine , Baden , Switzerland
| |
Collapse
|
3
|
VALKOVA K, Huellner M, Mueller D, Luyckx V, Schachtner T, Mueller T. POS-217 DEVELOPMENT OF A PROTOCOL FOR THE DYNAMIC MEASUREMENT OF RENAL FUNCTIONAL RESERVE. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
4
|
Luciani M, Mueller D, Vanetta C, Diteepeng T, Von Eckardstein A, Aeschbacher S, Rodondi N, Moschovitis G, Reichlin T, Bonati L, Luescher T, Kuehne M, Osswald S, Conen D, Beer J. Trimethylamine-N-oxide (TMAO) is associated with cardiovascular mortality and vascular brain lesions in patients with atrial fibrillation. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.0475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Trimethylamine-N-oxide (TMAO) is a well characterized pro-atherogenic metabolite derived from the microbial processing of phosphatidylcholine and carnitine (usually present in red meat) and subsequent hepatic oxydation, which promotes endothelial dysfunction, platelet activation and thrombosis initiation. Its role concerning cerebral and cardiovascular adverse events has been assessed in various patient subpopulations but not for long term in patients with atrial fibrillation.
Methods
Baseline TMAO plasma levels were measured by high-performance liquid chromatography/mass spectrometry in plasmas of 2,379 subjects from our multicentric study. Among them, 1,722 participants at time of recruitment underwent brain MRI. Participants were stratified into TMAO tertiles and Cox PH models, linear mixed effect models or logistic mixed effect models were employed adjusting for several risk factors (age, sex, BMI, active and past smoke habit, cystatin c levels, heart failure, diabetes mellitus, hypertension, coronary artery disease and history of TIA/stroke). Subjects were prospectively followed with a median observation time of 4 years.
Results
Subjects in the highest tertile of TMAO were older (75.4 vs. 70.6 years in low tertile p<0.001) and had significantly more often comorbidities, (26.9% of subjects were diabetic vs. 9.1% in low tertile p<0.001), with higher BMI (28.1 vs 27.0, p<0.001) and worse renal function as assessed by serum cystatin C (1.46 vs 1.07, mg/dl; p<0.001). Heart failure was present in 37.9% participants in the upper compared to 15.8% in the lower tertile. (p<0.001). As shown in Figure 1, Kaplan Meier estimates showed increased cardiovascular mortality with increasing TMAO tertiles (p<0.0001). After adjustment for the abovementioned factors the upper tertile (T3) had an increased hazard ratio (HR) compared to the lowest one (HR 2.36 95% CI 1.56–3.58 p<0.01). Similar trends for global and ischemic stroke occurrences were not found although TMAO levels positively weakly correlated with NIHSS severity (Spearman's coefficient 0.31 p=0.02). Concerning brain MRI findings, TMAO tertiles identified individuals with different prevalence of small non-cortical infarcts (30.5%, 18.1% and 17.4% in high, middle and low tertiles respectively; p<0.001) and when present, larger white matter lesions volumes (5061 mm3, 4158 mm3 and 2970 mm3; p<0.001). After adjustment, the association with small non-cortical infarcts with TMAO levels remained significant in the highest tertile (T3) (OR 1.48 95% CI 1.07–2.05; p=0.02) and a trend towards larger white matter lesions volumes was observed (estimate 1307 95% CI −90–2705; p=0.07).
Conclusions
TMAO represents a robust prognostic independent biomarker identifying multimorbid, high risk patients for cardiovascular mortality and brain damage.
Funding Acknowledgement
Type of funding sources: Public Institution(s). Main funding source(s): Swiss National Science Foundation (SNSF) and Theodor und Ida Herzog-Egli Foundation Figure 1. CV mortality according to TMAOFigure 2. Brain lesions assessment
Collapse
Affiliation(s)
- M Luciani
- Cantonal Hospital of Baden, Internal Medicine, Baden, Switzerland
| | - D Mueller
- University Hospital Zurich, Zurich, Switzerland
| | - C Vanetta
- Swiss Federal Institute of Technology Zurich (ETH Zurich), Zurich, Switzerland
| | - T Diteepeng
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | | | | | | | | | | | - L Bonati
- University Hospital Basel, Basel, Switzerland
| | - T.F Luescher
- University of Zurich, Center for Molecular Cardiology, Schlieren, Switzerland
| | - M Kuehne
- University Hospital Basel, Basel, Switzerland
| | - S Osswald
- University Hospital Basel, Basel, Switzerland
| | - D Conen
- Population Health Research Institute, Hamilton, Canada
| | - J.H Beer
- Cantonal Hospital of Baden, Internal Medicine, Baden, Switzerland
| | | |
Collapse
|
5
|
Berweck S, Bonikowski M, Kim H, Althaus M, Flatau-Baqué B, Mueller D, Banach MD. Placebo-Controlled Clinical Trial of IncobotulinumtoxinA for Sialorrhea in Children: SIPEXI. Neurology 2021; 97:e1425-e1436. [PMID: 34341153 PMCID: PMC8520391 DOI: 10.1212/wnl.0000000000012573] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2020] [Accepted: 07/06/2021] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES To investigate the efficacy and safety of repeated injections of incobotulinumtoxinA (incoBoNT/A) for treatment of chronic sialorrhea (drooling) associated with neurologic disorders (e.g., cerebral palsy, traumatic brain injury) or intellectual disability in children and adolescents in a prospective phase III study (SIPEXI [Sialorrhea Pediatric Xeomin Investigation]). METHODS The study enrolled 2- to 17-year-old patients with sialorrhea due to neurologic disorders or intellectual disability. Patients received body weight-dependent doses of incoBoNT/A (20-75 U). A main period with 1 injection cycle (placebo-controlled, double-blind, 6- to 17-year-olds) was followed by an open-label extension with up to 3 further cycles. An additional cohort of 2- to 5-year-olds received active treatment throughout the study. Coprimary endpoints were the change in unstimulated salivary flow rate (uSFR) from baseline to week 4 and the carers' Global Impression of Change Scale (GICS) rating at week 4. Adverse events were recorded. RESULTS In the main period, 220 patients aged 6-17 years were randomized and treated (148 patients in incoBoNT/A group, 72 patients in placebo group). A total of 35 patients aged 2-5 years received incoBoNT/A (no placebo). A total of 214 patients aged 6-17 years and 33 patients aged 2-5 years continued treatment in the open-label extension period. For the 6- to 17-year-olds, a significant difference between incoBoNT/A and placebo was seen in mean uSFR decrease (difference -0.06 g/min; p = 0.0012) and the carers' GICS rating (difference 0.28 points; p = 0.032) at week 4, in favor of active treatment. The secondary endpoints consistently supported these results. A sustained benefit was observed during the extension. Incidences of adverse events were comparable between incoBoNT/A and placebo and did not increase notably with repeated injections. The most common adverse events were respiratory infections. Efficacy and safety were also favorable in the uncontrolled cohort of 2- to 5-year-olds. DISCUSSION Both co-primary efficacy endpoints were reached and superiority of incoBoNT/A over placebo was confirmed. IncoBoNT/A (up to 75 U, up to 4 cycles) is an effective and well-tolerated treatment for sialorrhea associated with neurologic disorders in children. TRIAL REGISTRATION INFORMATION Clinicaltrials.gov: NCT02270736 (clinicaltrials.gov/ct2/show/results/NCT02270736); EU Clinical Trials Register: 2013-004532-30 (clinicaltrialsregister.eu/ctr-search/search?query=2013-004532-30). CLASSIFICATION OF EVIDENCE This study provides Class I evidence that injection of incobotulinumtoxinA decreases drooling in children aged 6 to 17 years with neurologic disorders.
Collapse
Affiliation(s)
- Steffen Berweck
- From the Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology (S.B.), Schoen Klinik, Vogtareuth; Department of Pediatric Neurology and Developmental Medicine (S.B.), LMU Center for Children with Medical Complexity-Integrated Social Pediatric Center, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Movement Analysis Lab, Neuro Rehabilitation Department (M.B.), Mazovian Neuropsychiatry Center LLC, Warsaw, Poland; Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine (H.K.), Columbia University Irving Medical Center/New York Presbyterian Hospital, New York; Merz Pharmaceuticals GmbH (M.A., B.F.-B.), Frankfurt am Main, Germany; Kantar Health (D.M.), Munich, Germany; and Department of Neurology (M.D.B.), Jagiellonian University, Krakow, Poland.
| | - Marcin Bonikowski
- From the Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology (S.B.), Schoen Klinik, Vogtareuth; Department of Pediatric Neurology and Developmental Medicine (S.B.), LMU Center for Children with Medical Complexity-Integrated Social Pediatric Center, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Movement Analysis Lab, Neuro Rehabilitation Department (M.B.), Mazovian Neuropsychiatry Center LLC, Warsaw, Poland; Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine (H.K.), Columbia University Irving Medical Center/New York Presbyterian Hospital, New York; Merz Pharmaceuticals GmbH (M.A., B.F.-B.), Frankfurt am Main, Germany; Kantar Health (D.M.), Munich, Germany; and Department of Neurology (M.D.B.), Jagiellonian University, Krakow, Poland
| | - Heakyung Kim
- From the Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology (S.B.), Schoen Klinik, Vogtareuth; Department of Pediatric Neurology and Developmental Medicine (S.B.), LMU Center for Children with Medical Complexity-Integrated Social Pediatric Center, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Movement Analysis Lab, Neuro Rehabilitation Department (M.B.), Mazovian Neuropsychiatry Center LLC, Warsaw, Poland; Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine (H.K.), Columbia University Irving Medical Center/New York Presbyterian Hospital, New York; Merz Pharmaceuticals GmbH (M.A., B.F.-B.), Frankfurt am Main, Germany; Kantar Health (D.M.), Munich, Germany; and Department of Neurology (M.D.B.), Jagiellonian University, Krakow, Poland
| | - Michael Althaus
- From the Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology (S.B.), Schoen Klinik, Vogtareuth; Department of Pediatric Neurology and Developmental Medicine (S.B.), LMU Center for Children with Medical Complexity-Integrated Social Pediatric Center, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Movement Analysis Lab, Neuro Rehabilitation Department (M.B.), Mazovian Neuropsychiatry Center LLC, Warsaw, Poland; Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine (H.K.), Columbia University Irving Medical Center/New York Presbyterian Hospital, New York; Merz Pharmaceuticals GmbH (M.A., B.F.-B.), Frankfurt am Main, Germany; Kantar Health (D.M.), Munich, Germany; and Department of Neurology (M.D.B.), Jagiellonian University, Krakow, Poland
| | - Birgit Flatau-Baqué
- From the Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology (S.B.), Schoen Klinik, Vogtareuth; Department of Pediatric Neurology and Developmental Medicine (S.B.), LMU Center for Children with Medical Complexity-Integrated Social Pediatric Center, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Movement Analysis Lab, Neuro Rehabilitation Department (M.B.), Mazovian Neuropsychiatry Center LLC, Warsaw, Poland; Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine (H.K.), Columbia University Irving Medical Center/New York Presbyterian Hospital, New York; Merz Pharmaceuticals GmbH (M.A., B.F.-B.), Frankfurt am Main, Germany; Kantar Health (D.M.), Munich, Germany; and Department of Neurology (M.D.B.), Jagiellonian University, Krakow, Poland
| | - Daniela Mueller
- From the Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology (S.B.), Schoen Klinik, Vogtareuth; Department of Pediatric Neurology and Developmental Medicine (S.B.), LMU Center for Children with Medical Complexity-Integrated Social Pediatric Center, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Movement Analysis Lab, Neuro Rehabilitation Department (M.B.), Mazovian Neuropsychiatry Center LLC, Warsaw, Poland; Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine (H.K.), Columbia University Irving Medical Center/New York Presbyterian Hospital, New York; Merz Pharmaceuticals GmbH (M.A., B.F.-B.), Frankfurt am Main, Germany; Kantar Health (D.M.), Munich, Germany; and Department of Neurology (M.D.B.), Jagiellonian University, Krakow, Poland
| | - Marta Dagmara Banach
- From the Specialist Center for Paediatric Neurology, Neurorehabilitation and Epileptology (S.B.), Schoen Klinik, Vogtareuth; Department of Pediatric Neurology and Developmental Medicine (S.B.), LMU Center for Children with Medical Complexity-Integrated Social Pediatric Center, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany; Movement Analysis Lab, Neuro Rehabilitation Department (M.B.), Mazovian Neuropsychiatry Center LLC, Warsaw, Poland; Pediatric Rehabilitation Medicine at the Department of Rehabilitation & Regenerative Medicine (H.K.), Columbia University Irving Medical Center/New York Presbyterian Hospital, New York; Merz Pharmaceuticals GmbH (M.A., B.F.-B.), Frankfurt am Main, Germany; Kantar Health (D.M.), Munich, Germany; and Department of Neurology (M.D.B.), Jagiellonian University, Krakow, Poland
| |
Collapse
|
6
|
Abdulkarim M, Grema HM, Adamu IH, Mueller D, Schulz M, Ulbrich M, Miocic JM, Preusser F. Effect of Using Different Chemical Dispersing Agents in Grain Size Analyses of Fluvial Sediments via Laser Diffraction Spectrometry. Methods Protoc 2021; 4:mps4030044. [PMID: 34209527 PMCID: PMC8293417 DOI: 10.3390/mps4030044] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 06/23/2021] [Accepted: 06/24/2021] [Indexed: 11/30/2022] Open
Abstract
Laser diffraction spectrometry allows for efficiently obtaining high-resolution grain size data. However, pretreatment and dispersion of aggregates in sediment samples are essential pre-requisites for acquiring accurate results using this method. This study evaluates the effectiveness of five dispersing agents in deflocculating the investigated fluvial sediments and the resulting grain size distribution obtained by laser diffraction spectrometry. We also examine the ability of the different dispersing agents to deflocculate sediment samples treated by thermal combustion. Distilled water presented a low efficiency in deflocculating the samples and yielded a near-zero clay content for samples with an expected clay content. The other chemical dispersants were effective in dispersing aggregates and yielding clay, albeit with different efficiencies. Calgon had the highest dispersing ability, followed closely by sodium tripolyphosphate. The performance of chemical treatment with sodium oxalate approaches that of sodium tripolyphosphate. However, it leads to the formation of precipitates in the samples, obscuring the actual grain size data. Sodium pyrophosphate derived the least amount of deflocculation among the four chemical dispersants. Furthermore, all the chemical dispersants were found to be ineffective in dispersing aggregates in samples treated by thermal combustion.
Collapse
Affiliation(s)
- Mubarak Abdulkarim
- Institute of Earth and Environmental Sciences, University of Freiburg, 79104 Freiburg, Germany; (D.M.); (M.S.); (M.U.); (F.P.)
- Department of Geology, Federal University Birnin Kebbi, Kalgo 862104, Nigeria
- Correspondence:
| | - Haruna M. Grema
- GFZ German Research Centre for Geosciences, 14473 Potsdam, Germany;
- Department of Geology, Faculty of Physical and Computing Science, Usmanu Danfodiyo University, Sokoto 840232, Nigeria;
| | - Ibrahim H. Adamu
- Department of Geology, Faculty of Physical and Computing Science, Usmanu Danfodiyo University, Sokoto 840232, Nigeria;
| | - Daniela Mueller
- Institute of Earth and Environmental Sciences, University of Freiburg, 79104 Freiburg, Germany; (D.M.); (M.S.); (M.U.); (F.P.)
| | - Melanie Schulz
- Institute of Earth and Environmental Sciences, University of Freiburg, 79104 Freiburg, Germany; (D.M.); (M.S.); (M.U.); (F.P.)
| | - Marius Ulbrich
- Institute of Earth and Environmental Sciences, University of Freiburg, 79104 Freiburg, Germany; (D.M.); (M.S.); (M.U.); (F.P.)
| | - Johannes M. Miocic
- Energy and Sustainability Research Institute Groningen (ESRIG), University of Groningen, 9747 AG Groningen, The Netherlands;
| | - Frank Preusser
- Institute of Earth and Environmental Sciences, University of Freiburg, 79104 Freiburg, Germany; (D.M.); (M.S.); (M.U.); (F.P.)
| |
Collapse
|
7
|
Hahn SH, Han H, Woo M, Bak J, Chung J, Jeon Y, Jeong J, Joung M, Juhn J, Kim H, Kim H, Lee M, Shin G, Tak T, Yoon S, Barr J, Eidietis N, Humphreys D, Hyatt A, Penaflor B, Piglowski D, Walker M, Welander A, Boyer M, Erickson K, Mueller D. Advances and challenges in KSTAR plasma control toward long-pulse, high-performance experiments. Fusion Engineering and Design 2020. [DOI: 10.1016/j.fusengdes.2020.111622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
8
|
Deibl S, Mueller D, Kirchdorfer K, Stemer G, Hoppel M, Weidmann AE. Self-reported clinical pharmacy service provision in Austria: an analysis of both the community and hospital pharmacy sector-a national study. Int J Clin Pharm 2020; 42:1050-1060. [PMID: 32494989 DOI: 10.1007/s11096-020-01066-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 05/23/2020] [Indexed: 12/28/2022]
Abstract
Background With expansion of more advanced clinical roles for pharmacists we need to be mindful that the extent to which clinical pharmacy services are implemented varies from one country to another. To date no comprehensive assessment of number and types of services provided by either community or hospital pharmacies in Austria exists. Objective To analyse and describe the number and types of clinical pharmacy services provided in both community and hospital pharmacies, as well as the level of clinical pharmacy education of pharmacists across Austria. Setting Austrian community and hospital pharmacies. Method An electronic questionnaire to determine number and types of clinical pharmacy services provided was send to all chief pharmacists at all community (n = 1365) and hospital pharmacies (n = 40) across Austria. Besides current and future services provision, education and training provision were also assessed. Main outcome measure Extent of and attitude towards CPS in Austria. Results Response rates to the surveys were 19.1% (n = 261/1365) in community and 92.5% (n = 37/40) in hospital pharmacies. 59.0% and 89.2% of community and hospital pharmacies, respectively, indicated that the provision of clinical pharmacy services in Austria has increased substantially over the past 10 years. Fifty-one percent of community pharmacies reported to provide a medication review service, while 97.3% of hospitals provide a range of services. Only 18.0% of community pharmacies offer services other than medication review services at dispensing. Binary regressions show that provision of already established medication management is a predictor for the willingness of community pharmacists to extend the range of CPS (p < 0.01), while completed training in the area of clinical pharmacy is not (p > 0.05). More hospital than community pharmacists have postgraduate education in clinical pharmacy (17.4% vs 6.5%). A desire to complete postgraduate education was shown by 28.3% of community and 14.7% of hospital pharmacists. Lack of time, inadequate remuneration, lack of resources and poor relationship between pharmacists and physicians were highlighted as barriers. Conclusion Both community and hospital pharmacists show strong willingness to expand their service provision and will need continued support, such as improved legislative structures, more supportive resources and practice focused training opportunities, to further these services.
Collapse
Affiliation(s)
- S Deibl
- Österreichische Apothekerkammer, Spitalgasse 31, Postfach 87, 1091, Vienna, Austria.
| | - D Mueller
- Vienna Pharmacy Department, Hanusch-Hospital, Heinrich Collin-Straße 30, 1140, Vienna, Austria
| | - K Kirchdorfer
- Vienna Pharmacy Department, Hanusch-Hospital, Heinrich Collin-Straße 30, 1140, Vienna, Austria
| | - G Stemer
- Pharmacy Department, Vienna General Hospital - Medical University Campus, Währinger Gürtel 18-20, 1090, Vienna, Austria
| | - M Hoppel
- Österreichische Apothekerkammer, Spitalgasse 31, Postfach 87, 1091, Vienna, Austria
| | - A E Weidmann
- School of Pharmacy and Life Sciences, Robert Gordon University, Aberdeen, UK
| |
Collapse
|
9
|
Meyre P, Gugganig R, Aeschbacher S, Leong DP, Blum S, Coslovsky M, Beer JH, Moschovitis G, Mueller D, Rodondi N, Stempfel S, Mueller C, Kuehne M, Conen D, Osswald S. P3782Frailty to predict unplanned hospitalizations, stroke, bleeding and death in atrial fibrillation. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.0631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aim
We investigated the prevalence of frailty, and the relationships between frailty and the risk of adverse clinical outcomes in patients with atrial fibrillation (AF).
Methods
Patients with known AF were enrolled in a nation-wide observational cohort study in Switzerland. Information on medical history, medication, lifestyle factors and clinical measurements were obtained. The primary outcome was unplanned hospitalizations, secondary outcomes were all-cause mortality, bleeding and stroke. The frailty index (FI) was measured using a cumulative deficit approach according to previously published criteria. Participants were divided into three groups (non-frail, pre-frail and frail) according to their FI at study entry. The association between frailty and clinical outcomes was assessed using multivariable adjusted Cox proportional hazard models.
Results
We included 2369 patients with a mean age of 73±8 years (27.3% female). The prevalence of frailty and pre-frailty was 10.6% and 60.7%, respectively. Frailty was associated with unplanned hospitalization (adjusted hazard ratio [HR] 3.59; 95% confidence interval [95% CI], 2.78–4.63; p<0.001), all-cause mortality (adjusted HR 16.72; 95% CI 7.75–36.05; p<0.001), bleeding (adjusted HR 2.46; 95% CI 1.61–3.77; p<0.001), and stroke (adjusted HR 3.29; 95% CI 1.29–8.39; p=0.01) (Figure). Similarly, pre-frailty was significantly associated with unplanned hospitalization (adjusted HR 1.82; 95% CI 1.49–2.22; p<0.001), all-cause mortality (adjusted HR 5.07; 95% CI 2.43–10.59; p<0.001) and bleeding (adjusted HR 1.53; 95% CI 1.11–2.13; p=0.01), but not with stroke.
Cumulative incidence of adverse events
Conclusion
In our cohort, more than two thirds of AF patients were either pre-frail or frail. These patients have a high risk of unplanned hospitalizations and other adverse outcomes, indicating that frailty is a powerful tool to predict adverse clinical outcomes in AF patients.
Acknowledgement/Funding
Swiss National Science Foundation; Foundation for Cardiovascular Research Basel; University of Basel
Collapse
Affiliation(s)
- P Meyre
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - R Gugganig
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - S Aeschbacher
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - D P Leong
- McMaster University, Population Health Research Institute, Hamilton, Canada
| | - S Blum
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - M Coslovsky
- University Hospital Basel, Department of Clinical Research, Basel, Switzerland
| | - J H Beer
- Cantonal Hospital of Baden, Department of Medicine, Baden, Switzerland
| | - G Moschovitis
- Lugano Regional Hospital, Department of Cardiology, Lugano, Switzerland
| | - D Mueller
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - N Rodondi
- Bern University Hospital, Department of General Medicine, Bern, Switzerland
| | - S Stempfel
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - C Mueller
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - M Kuehne
- University Hospital Basel, Cardiology, Basel, Switzerland
| | - D Conen
- McMaster University, Population Health Research Institute, Hamilton, Canada
| | - S Osswald
- University Hospital Basel, Cardiology, Basel, Switzerland
| |
Collapse
|
10
|
Mueller D, Hahn S, Eidietis N, Bak J, Boyer M, Humphreys D, Hyatt A, Jeon Y, Kim H, Walker M. Improved fast vertical control in KSTAR. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.02.046] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
11
|
Hawryluk R, Barnes CW, Batha S, Beer M, Bell M, Bell R, Berk H, Bitter M, Bretz N, Budny R, Bush C, Cauffman S, Chang CS, Chang Z, Cheng C, Darrow D, Dendy R, Dorland W, Dudek L, Duong H, Durst R, Efthimion P, Evenson H, Fisch N, Fisher R, Fonck R, Forrest C, Fredrickson E, Fu G, Furth H, Gorelenkov N, Grek B, Grisham L, Hammett G, Heidbrink W, Herrmann H, Herrmann M, Hill K, Hooper B, Hosea J, Houlberg W, Hughes M, Jassby D, Jobes F, Johnson D, Kaita R, Kamperschroer J, Kesner J, Krazilniknov A, Kugel H, Kumar A, LaMarche P, LeBlanc B, Levine J, Levinton F, Lin Z, Machuzak J, Majeski R, Mansfield D, Mazzucato E, Mauel M, McChesney J, McGuire K, McKee G, Meade D, Medley S, Mikkelsen D, Mimov S, Mueller D, Navratil G, Nazikian R, Nevins B, Okabayashi M, Osakabe M, Owens D, Park H, Park W, Paul S, Petrov M, Phillips C, Phillips M, Phillips P, Ramsey A, Redi M, Rewoldt G, Rice B, Rogers J, Roquemore A, Ruskov E, Sabbagh S, Sasao M, Schilling G, Schmidt G, Scott S, Semenov I, Skinner C, Spong D, Strachan J, Strait E, Stratton B, Synakowski E, Takahashi H, Tang W, Taylor G, Goeler SV, Halle AV, White R, Williams M, Wilson J, Wong K, Wurden G, Young K, Zarnstorff M, Zweben S. Review of D-T Results from TFTR. ACTA ACUST UNITED AC 2018. [DOI: 10.13182/fst96-a11963011] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
12
|
van Schaik IN, Bril V, van Geloven N, Hartung HP, Lewis RA, Sobue G, Lawo JP, Praus M, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, Sabet A, George K, Roberts L, Carne R, Blum S, Henderson R, Van Damme P, Demeestere J, Larue S, D'Amour C, Bril V, Breiner A, Kunc P, Valis M, Sussova J, Kalous T, Talab R, Bednar M, Toomsoo T, Rubanovits I, Gross-Paju K, Sorro U, Saarela M, Auranen M, Pouget J, Attarian S, Le Masson G, Wielanek-Bachelet A, Desnuelle C, Delmont E, Clavelou P, Aufauvre D, Schmidt J, Zschuentssch J, Sommer C, Kramer D, Hoffmann O, Goerlitz C, Haas J, Chatzopoulos M, Yoon R, Gold R, Berlit P, Jaspert-Grehl A, Liebetanz D, Kutschenko A, Stangel M, Trebst C, Baum P, Bergh F, Klehmet J, Meisel A, Klostermann F, Oechtering J, Lehmann H, Schroeter M, Hagenacker T, Mueller D, Sperfeld A, Bethke F, Drory V, Algom A, Yarnitsky D, Murinson B, Di Muzio A, Ciccocioppo F, Sorbi S, Mata S, Schenone A, Grandis M, Lauria G, Cazzato D, Antonini G, Morino S, Cocito D, Zibetti M, Yokota T, Ohkubo T, Kanda T, Kawai M, Kaida K, Onoue H, Kuwabara S, Mori M, Iijima M, Ohyama K, Baba M, Tomiyama M, Nishiyama K, Akutsu T, Yokoyama K, Kanai K, van Schaik I, Eftimov F, Notermans N, Visser N, Faber C, Hoeijmakers J, Rejdak K, Chyrchel-Paszkiewicz U, Casanovas Pons C, Alberti Aguiló M, Gamez J, Figueras M, Marquez Infante C, Benitez Rivero S, Lunn M, Morrow J, Gosal D, Lavin T, Melamed I, Testori A, Ajroud-Driss S, Menichella D, Simpson E, Chi-Ho Lai E, Dimachkie M, Barohn R, Beydoun S, Johl H, Lange D, Shtilbans A, Muley S, Ladha S, Freimer M, Kissel J, Latov N, Chin R, Ubogu E, Mumfrey S, Rao T, MacDonald P, Sharma K, Gonzalez G, Allen J, Walk D, Hobson-Webb L, Gable K. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2018; 17:35-46. [DOI: 10.1016/s1474-4422(17)30378-2] [Citation(s) in RCA: 130] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Revised: 09/28/2017] [Accepted: 10/02/2017] [Indexed: 10/18/2022]
|
13
|
Koenig A, Krug S, Mueller D, Barth PJ, Koenig U, Scharf M, Ellenrieder V, Michl P, Moll R, Homayunfar K, Kann PH, Stroebel P, Gress TM, Rinke A. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms. PLoS One 2017; 12:e0188876. [PMID: 29232390 PMCID: PMC5726657 DOI: 10.1371/journal.pone.0188876] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2017] [Accepted: 11/14/2017] [Indexed: 12/29/2022] Open
Abstract
Chromogranin A (CgA) is a well-established marker for diagnosis and follow up of patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN). Recently, it has been shown that plasma levels of CgA correlate with tumor load and predict survival of patients with NEN of the small bowel. It is assumed that this is as well valid for NEN of the colon and rectum, however, this is not supported by data. To evaluate this assumption, we analyzed 62 patients with NEN of the colon and rectum listed in the Marburg GEP-NEN registry for clinicopathological characteristics, expression and plasma levels of CgA. The present study demonstrates that immunohistochemical CgA and synaptophysin are good markers for histological diagnosis in patients with NEN of the colon and rectum. However, plasma CgA is a poor marker to follow-up these patients because only a minority exhibited increased levels which did not increase significantly during tumor progression. In contrast to NEN of the small bowel, there is no correlation of CgA plasma levels with tumor burden or survival. Patients with NEN of the colon and rectum displayed a relatively good prognosis resulting in a median survival of 8.5 years. However, a subset of patients affected by G3 neoplasms, exhibited a poorer prognosis with a median survival of 2.5 years. Taken together, CgA is a valuable marker for immunohistochemical diagnosis, but CgA plasma concentration is not suitable to mirror tumor burden or prognosis in patients with NEN of the colon and rectum.
Collapse
Affiliation(s)
- Alexander Koenig
- Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany
- Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany
- * E-mail: (AK); (AR)
| | - Sebastian Krug
- Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany
- Department of Internal Medicine I, University Halle, Halle, Germany
| | - Daniela Mueller
- Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany
| | - Peter J. Barth
- Gerhard-Domagk-Institute of Pathology, University of Muenster, Muenster, Germany
- Department of Pathology, Philipps-University of Marburg, Marburg, Germany
| | - Ute Koenig
- Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany
| | - Michael Scharf
- Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany
| | - Volker Ellenrieder
- Department of Gastroenterology and Gastrointestinal Oncology, University Medical Center Goettingen, Goettingen, Germany
| | - Patrick Michl
- Department of Internal Medicine I, University Halle, Halle, Germany
| | - Roland Moll
- Department of Pathology, Philipps-University of Marburg, Marburg, Germany
| | - Kia Homayunfar
- Department of General-, Visceral- and Pediatric Surgery University Medical Center Goettingen, Goettingen, Germany
| | - Peter Herbert Kann
- Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany
| | - Philipp Stroebel
- Department of Pathology, University Medical Center Goettingen, Goettingen, Germany
| | - Thomas M. Gress
- Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany
| | - Anja Rinke
- Department of Gastroenterology and Endocrinology, Philipps-University of Marburg, Marburg, Germany
- * E-mail: (AK); (AR)
| |
Collapse
|
14
|
Granic M, Suton P, Mueller D, Cvrljevic I, Luksic I. Prognostic factors in head and neck mucoepidermoid carcinoma: experience at a single institution based on 64 consecutive patients over a 28-year period. Int J Oral Maxillofac Surg 2017; 47:283-288. [PMID: 28969884 DOI: 10.1016/j.ijom.2017.09.005] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 07/19/2017] [Accepted: 09/11/2017] [Indexed: 01/03/2023]
Abstract
Mucoepidermoid carcinoma (MEC) is the most common malignancy of the salivary glands. The clinical behaviour of MEC is largely unpredictable, ranging from indolent tumour growth to highly aggressive metastatic spread. The objective of this study was to determine the clinicopathological predictors of recurrence and survival in patients with head and neck MEC. The medical records of 64 patients who underwent surgical treatment for head and neck MEC between 1982 and 2010 were reviewed. The main outcome measures were disease-free survival (DFS) and overall survival (OS). Clinicopathological parameters evaluated were age, sex, anatomical subsite, histological grade, tumour stage, tumour size, adjuvant therapy, and nodal and margin status. For the entire cohort, the 5-year DFS was 82.8% and the 5-year OS was 67.2%. Histological grade and tumour subsite were statistically significant predictors of OS. Furthermore, tumour stage and nodal status were statistically significant predictors with respect to OS. Advanced tumour stage, high histological grade, submandibular/sublingual localization, and positive nodal status were independent predictors of the prognosis in patients with head and neck MEC. Further studies into the molecular biology of MEC are needed in order to provide new therapeutic strategies for patients with locally aggressive and highly metastatic carcinomas.
Collapse
Affiliation(s)
- M Granic
- Department of Oral Surgery, University of Zagreb School of Dental Medicine, Zagreb, Croatia
| | - P Suton
- Department of Radiotherapy and Medical Oncology, Division of Radiation Oncology, University Hospital for Tumours, University Hospital Centre "Sisters of Mercy", Zagreb, Croatia
| | - D Mueller
- Department of Pathology, University Hospital Dubrava, Zagreb, Croatia
| | - I Cvrljevic
- Department of Maxillofacial Surgery, University of Zagreb School of Medicine, University Hospital Dubrava, Zagreb, Croatia
| | - I Luksic
- Department of Maxillofacial Surgery, University of Zagreb School of Medicine, University Hospital Dubrava, Zagreb, Croatia.
| |
Collapse
|
15
|
Murakami M, Arunasalam V, Bell J, Bell M, Bitter M, Blanchard W, Boody F, Boyd D, Bretz N, Bush C, Callen J, Cecchi J, Colchin R, Coonrod J, Davis S, Dimock D, Dylla H, Efthimion P, Emerson L, England A, Eubank H, Fonck R, Fredrickson E, Furth H, Grisham L, von Goeler S, Goldston R, Grek B, Grove D, Hawryluk R, Hendel H, Hill K, Hulse R, Johnson D, Johnson L, Kaita R, Kamperschroer J, Kaye S, Kikuchi M, Kilpatrick S, Kugel H, LaMarche P, Little R, Ma C, Manos D, Mansfield D, McCarthy M, McCann R, McCune D, McGuire K, Meade D, Medley S, Mikkelsen D, Mueller D, Nieschmidt E, Owens D, Pare V, Park H, Prichard B, Ramsey A, Rasmussen D, Roquemore A, Rutherford P, Sauthoff N, Schivell J, Schwob JL, Scott S, Sesnic S, Shimada M, Simpkins J, Sinnis J, Stauffer F, Stratton B, Suckewer S, Tait G, Taylor G, Tenney F, Thomas C, Towner H, Ulrickson M, Wieland R, Williams M, Wong KL, Wouters A, Yamada H, Yoshikawa S, Young K, Zarnstorff M. Confinement Studies In TFTR. ACTA ACUST UNITED AC 2017. [DOI: 10.13182/fst85-a40115] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- M. Murakami
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - V. Arunasalam
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J.D. Bell
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - M.G. Bell
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Bitter
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - W.R. Blanchard
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - F. Boody
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Boyd
- Permanent Address: University of Maryland, College Park, MD
| | - N. Bretz
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - C.E. Bush
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - J.D. Callen
- Permanent Address: University of Wisconsin, Madison, WI
| | - J.L. Cecchi
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.J. Colchin
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - J. Coonrod
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S.L. Davis
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Dimock
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H.F. Dylla
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - P.C. Efthimion
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - L.C. Emerson
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - A.C. England
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - H.P. Eubank
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Fonck
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - E. Fredrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H.P. Furth
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - L.R. Grisham
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S. von Goeler
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.J. Goldston
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - B. Grek
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.J. Grove
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.J. Hawryluk
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H. Hendel
- Permanent Address: RCA David Sarnoff Research Center, Princeton, NJ
| | - K.W. Hill
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Hulse
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - L.C. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Kaita
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J. Kamperschroer
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S.M. Kaye
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Kikuchi
- Permanent Address: Japan Atomic Energy Research Institute, Japan
| | - S. Kilpatrick
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H. Kugel
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - P.H. LaMarche
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Little
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - C.H. Ma
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - D. Manos
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Mansfield
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. McCarthy
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R.T. McCann
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.C. McCune
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - K. McGuire
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.M. Meade
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S.S. Medley
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.R. Mikkelsen
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D. Mueller
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | | | - D.K. Owens
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - V.K. Pare
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - H. Park
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - B. Prichard
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - A. Ramsey
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - D.A. Rasmussen
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - A.L. Roquemore
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - P.H. Rutherford
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - N.R. Sauthoff
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J. Schivell
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - J-L. Schwob
- Permanent Address: Hebrew University of Jerusalem, Israel
| | - S.D Scott
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S. Sesnic
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Shimada
- Permanent Address: Japan Atomic Energy Research Institute, Japan
| | - J.E. Simpkins
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - J. Sinnis
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - F. Stauffer
- Permanent Address: University of Maryland, College Park, MD
| | - B. Stratton
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - S. Suckewer
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - G.D. Tait
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - G. Taylor
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - F. Tenney
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - C.E. Thomas
- Permanent Address: Oak Ridge National Laboratory, Oak Ridge, TN
| | - H.H. Towner
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Ulrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - R. Wieland
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M. Williams
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - K-L. Wong
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - A. Wouters
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - H. Yamada
- Permanent Address: Univeristy of Tokyo, Japan
| | - S. Yoshikawa
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - K.M Young
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| | - M.C. Zarnstorff
- Plasma Physics Laboratory, Princeton University P.O. Box 451, Princeton, NJ 08544
| |
Collapse
|
16
|
Hawryluk RJ, Mueller D, Hosea J, Barnes CW, Beer M, Bell MG, Bell R, Biglari H, Bitter M, Boivin R, Bretz NL, Budny R, Bush CE, Chen L, Cheng CZ, Cowley S, Dairow DS, Efthimion PC, Fonck RJ, Fredrickson E, Furth HP, Greene G, Grek B, Grisham LR, Hammett G, Heidbrink W, Hill KW, Hoffman D, Hulse RA, Hsuan H, Janos A, Jassby DL, Jobes FC, Johnson DW, Johnson LC, Kamperschroer J, Kesner J, Phillips CK, Kilpatrick SJ, Kugel H, LaMarche PH, LeBlanc B, Manos DM, Mansfield DK, Marmar ES, Mazzucato E, McCarthy MP, Machuzak J, Mauel M, McCune D, McGuire KM, Medley SS, Monticello DR, Mikkelsen D, Nagayama Y, Navratil GA, Nazikian R, Owens DK, Park H, Park W, Paul S, Perkins F, Pitcher S, Rasmussen D, Redi MH, Rewoldt G, Roberts D, Roquemore AL, Sabbagh S, Schilling G, Schivell J, Schmidt GL, Scott SD, Snipes J, Stevens J, Stratton BC, Strachan JD, Stodiek W, Synakowski E, Tang W, Taylor G, Terry J, Timberlake JR, Ulrickson HH, Towner M, von Goeler S, Wieland R, Wilson JR, Wong KL, Woskov P, Yamada M, Young KM, Zamstorff MC, Zweben SJ. Status and Plans for TFTR. ACTA ACUST UNITED AC 2017. [DOI: 10.13182/fst92-a29907] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- R. J. Hawryluk
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. Mueller
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Hosea
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - M. Beer
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. G. Bell
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Bell
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Biglari
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. Bitter
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Boivin
- Massachusetts Institute of Technology, Cambridge, MA
| | - N. L. Bretz
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Budny
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - C. E. Bush
- Oak Ridge National Laboratory, Oak Ridge, TN
| | - L. Chen
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - C. Z. Cheng
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. Cowley
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. S. Dairow
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - P. C. Efthimion
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - E. Fredrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. P. Furth
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Greene
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - B. Grek
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - L. R. Grisham
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Hammett
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - K. W. Hill
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. Hoffman
- Oak Ridge National Laboratory, Oak Ridge, TN
| | - R. A. Hulse
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Hsuan
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - A. Janos
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. L. Jassby
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - F. C. Jobes
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. W. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - L. C. Johnson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Kamperschroer
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Kesner
- Massachusetts Institute of Technology, Cambridge, MA
| | - C. K. Phillips
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. J. Kilpatrick
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Kugel
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - P. H. LaMarche
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - B. LeBlanc
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. M. Manos
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. K. Mansfield
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - E. S. Marmar
- Massachusetts Institute of Technology, Cambridge, MA
| | - E. Mazzucato
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. P. McCarthy
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Machuzak
- Massachusetts Institute of Technology, Cambridge, MA
| | - M. Mauel
- Columbia University, New York, NY
| | - D.C. McCune
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - K. M. McGuire
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. S. Medley
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. R. Monticello
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. Mikkelsen
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | | | - R. Nazikian
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - D. K. Owens
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. Park
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - W. Park
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. Paul
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - F. Perkins
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. Pitcher
- Canadian Fusion Fuels Technology Project, Toronto, Canada
| | | | - M. H. Redi
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Rewoldt
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - A. L. Roquemore
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | | | - G. Schilling
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Schivell
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. L. Schmidt
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. D. Scott
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Snipes
- Massachusetts Institute of Technology, Cambridge, MA
| | - J. Stevens
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - B. C. Stratton
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. D. Strachan
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - W. Stodiek
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - E. Synakowski
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - W. Tang
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - G. Taylor
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. Terry
- Massachusetts Institute of Technology, Cambridge, MA
| | - J. R. Timberlake
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - H. H. Ulrickson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. Towner
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. von Goeler
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - R. Wieland
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - J. R. Wilson
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - K. L. Wong
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - P. Woskov
- Massachusetts Institute of Technology, Cambridge, MA
| | - M. Yamada
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - K. M. Young
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - M. C. Zamstorff
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| | - S. J. Zweben
- Plasma Physics Laboratory, Princeton University P.O. Box 451 Princeton, N.J. 08543 USA (609) 243-3306
| |
Collapse
|
17
|
Schaerli N, Honegger U, Abaecherli R, Rinderknecht T, Mueller D, Twerenbold R, Pretre G, Wagener M, Puelacher C, Strebel I, Leber R, Osswald S, Zellweger M, Mueller C, Reichlin T. P6373Incremental diagnostic value of high-frequency QRS analysis for the detection of exercise induced myocardial ischemia. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p6373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Reiner M, Mueller D, Gobbato S, Stalder O, Limacher A, Bonetti N, Stivala S, Mean M, Rodondi N, Aujesky D, Luescher T, Camici G, Von Eckardstein A, Beer J. P5320Trimethylamine-N-oxide (TMAO) Predicts Total Mortality, but not Recurrent Venous Thromboembolism in Elderly Patients with Acute Venous Thromboembolism. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5320] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Hamzic S, Kummer D, Milesi S, Mueller D, Joerger M, Aebi S, Amstutz U, Largiader CR. Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. Clin Pharmacol Ther 2017; 102:796-804. [DOI: 10.1002/cpt.641] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 01/20/2017] [Accepted: 01/23/2017] [Indexed: 12/19/2022]
Affiliation(s)
- S Hamzic
- Institute of Clinical Chemistry; Inselspital, Bern University Hospital, University of Bern; Bern Switzerland
- Graduate School for Cellular and Biomedical Sciences; University of Bern; Bern Switzerland
| | - D Kummer
- Institute of Clinical Chemistry; Inselspital, Bern University Hospital, University of Bern; Bern Switzerland
- Graduate School for Cellular and Biomedical Sciences; University of Bern; Bern Switzerland
| | - S Milesi
- Institute of Clinical Chemistry; Inselspital, Bern University Hospital, University of Bern; Bern Switzerland
| | - D Mueller
- Institute of Clinical Chemistry; Inselspital, Bern University Hospital, University of Bern; Bern Switzerland
| | - M Joerger
- Department of Medical Oncology and Hematology; Cantonal Hospital St. Gallen; St. Gallen Switzerland
| | - S Aebi
- Division of Medical Oncology; Cantonal Hospital Lucerne; Lucerne Switzerland
| | - U Amstutz
- Institute of Clinical Chemistry; Inselspital, Bern University Hospital, University of Bern; Bern Switzerland
| | - CR Largiader
- Institute of Clinical Chemistry; Inselspital, Bern University Hospital, University of Bern; Bern Switzerland
| |
Collapse
|
20
|
Leuer JA, Xiao BJ, Humphreys DA, Walker ML, Hyatt AW, Jackson GL, Mueller D, Penaflor BG, Piglowski DA, Johnson RD, Welander AS, Yuan QP, Wang HZ, Luo JR. Tokamak Start-Up Modeling and Design for EAST First Plasma Campaign. Fusion Science and Technology 2017. [DOI: 10.13182/fst10-a9268] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- J. A. Leuer
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - B. J. Xiao
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei, China
| | - D. A. Humphreys
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - M. L. Walker
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - A. W. Hyatt
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - G. L. Jackson
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - D. Mueller
- Princeton Plasma Physics Laboratory, Princeton, New Jersey
| | - B. G. Penaflor
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - D. A. Piglowski
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - R. D. Johnson
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - A. S. Welander
- General Atomics, P.O. Box 85608, San Diego, California 92186-5608
| | - Q. P. Yuan
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei, China
| | - H. Z. Wang
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei, China
| | - J. R. Luo
- Institute of Plasma Physics, Chinese Academy of Sciences, Hefei, China
| | | |
Collapse
|
21
|
Yang HL, Kwak JG, Oh YK, Park KR, Kim WC, Lee SG, Kim JY, Bae YS, Park YM, Kim HK, Chu Y, Park MK, Kim JS, In SR, Joung SH, Choe WH, Park HK, Hwang YS, Na YS, Park JG, Ahn JW, Park YS, Kwon M, Leuer JA, Eidietis NW, Hyatt AW, Walker M, Gorelov Y, Lohr J, Mueller D, Grisham LR, Sabbagh SA, Watanabe K, Inoue T, Sakamoto K, Oda Y, Kajiwara K, Ellis R, Hosea J, Delpech L, Hoang TT, Litaudon X, Namkung W, Cho MH. Overview of KSTAR Results in Phase-I Operation. Fusion Science and Technology 2017. [DOI: 10.13182/fst13-a19130] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- H. L. Yang
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. G. Kwak
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. K. Oh
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - K. R. Park
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - W. C. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - S. G. Lee
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. Y. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. S. Bae
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. M. Park
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - H. K. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - Y. Chu
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - M. K. Park
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. S. Kim
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - S. R. In
- Korea Atomic Energy Research Insititute, Daeduk-Daero 989-111, Yuseong-gu, Daejeon, 305-353, Korea
| | - S. H. Joung
- Korea Atomic Energy Research Insititute, Daeduk-Daero 989-111, Yuseong-gu, Daejeon, 305-353, Korea
| | - W. H. Choe
- Korea Advanced Institute of Science and Technology, 291 Daehak-ro, Yuseong-gu, Daejeon, 305-701, Korea
| | - H. K. Park
- Pohang Univ. of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang, Gyungbuk, 790-784, Korea
| | - Y. S. Hwang
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742, Korea
| | - Y. S. Na
- Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul, 151-742, Korea
| | - J. G. Park
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - J. W. Ahn
- Oak Ridge National Lab., 1 Bethal Valley Rd, OakRidge, TN37831, USA
| | - Y. S. Park
- Columbia Univ., James Forrestal Campus (EWA 244), P.O. Box 451, Princeton, NJ 08543, USA
| | - M. Kwon
- National Fusion Research Institute, 113 Gwahangno, Yusung-Gu, Daejeon, 305-333, Korea
| | - J. A. Leuer
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - N. W. Eidietis
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - A. W. Hyatt
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - M. Walker
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - Y. Gorelov
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - J. Lohr
- General Atomics, 3550 General Atomics Court, San Diego, CA 92121, USA
| | - D. Mueller
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - L. R. Grisham
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - S. A. Sabbagh
- Columbia Univ., James Forrestal Campus (EWA 244), P.O. Box 451, Princeton, NJ 08543, USA
| | - K. Watanabe
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - T. Inoue
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - K. Sakamoto
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - Y. Oda
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - K. Kajiwara
- Japan Atomic Energy Agency, 801-1 Mukoyama, Naka-city, Ibaraki-ken, 311-0193, Japan
| | - R. Ellis
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - J. Hosea
- Princeton Plasma Physics Lab., P.O. Box 451 Princetorn, NJ 08543-0451, USA
| | - L. Delpech
- CEA, IFRM,13108 Saint-Paul-Lez-Durance, France
| | - T. T. Hoang
- CEA, IFRM,13108 Saint-Paul-Lez-Durance, France
| | - X. Litaudon
- CEA, IFRM,13108 Saint-Paul-Lez-Durance, France
| | - W. Namkung
- Pohang Univ. of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang, Gyungbuk, 790-784, Korea
| | - M. H. Cho
- Pohang Univ. of Science and Technology, 77 Cheongam-ro, Nam-gu, Pohang, Gyungbuk, 790-784, Korea
| | | |
Collapse
|
22
|
Gerhardt SP, Mastrovito D, Bell MG, Cropper M, Gates DA, Kolemen E, Lawson J, Marsala B, Menard JE, Mueller D, Stevenson T. Implementation of βN Control in the National Spherical Torus Experiment. Fusion Science and Technology 2017. [DOI: 10.13182/fst12-a13336] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- S. P. Gerhardt
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - D. Mastrovito
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - M. G. Bell
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - M. Cropper
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - D. A. Gates
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - E. Kolemen
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - J. Lawson
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - B. Marsala
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - J. E. Menard
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - D. Mueller
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| | - T. Stevenson
- Princeton Plasma Physics Laboratory, P.O. Box 451, Princeton, New Jersey 08543
| |
Collapse
|
23
|
Mueller D, Kulkarni H, Baum RP, Odparlik A. Rapid Synthesis of 68Ga-labeled macroaggregated human serum albumin (MAA) for routine application in perfusion imaging using PET/CT. Appl Radiat Isot 2017; 122:72-77. [PMID: 28113072 DOI: 10.1016/j.apradiso.2017.01.003] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2016] [Revised: 12/21/2016] [Accepted: 01/06/2017] [Indexed: 11/16/2022]
Abstract
99mTc-labeled MAA is commonly used for single photon emission computed tomography SPECT. In contrast, positron emission tomography/CT (PET/CT) delivers images with significantly higher resolution. The generator produced radionuclide 68Ga is widely used for PET/CT imaging agents and 68Ga-labeled MAA represents an attractive alternative to 99mTc-labeled MAA. We report a simple and rapid NaCl based labeling procedure for the labeling of MAA with 68Ga using a commercially available MAA labeling kit for 99mTc. The procedure delivers 68Ga-labeled MAA with a high specific activity and a high labeling efficiency (>99%). The synthesis does not require a final step of separation or the use of organic solvents.
Collapse
Affiliation(s)
- D Mueller
- Department of Radiophamacy, Zentralklinik Bad Berka, Germany.
| | - Harshad Kulkarni
- Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Germany
| | - Richard P Baum
- Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Germany
| | - Andreas Odparlik
- Department of Nuclear Medicine, University Hospital Halle(Saale), Germany
| |
Collapse
|
24
|
Alarhayem A, Myers J, Dent D, Liao L, Muir M, Mueller D, Nicholson S, Cestero R, Johnson M, Stewart R, O'Keefe G, Eastridge B. Time is the enemy: Mortality in trauma patients with hemorrhage from torso injury occurs long before the “golden hour”. Am J Surg 2016; 212:1101-1105. [DOI: 10.1016/j.amjsurg.2016.08.018] [Citation(s) in RCA: 96] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Accepted: 08/24/2016] [Indexed: 10/20/2022]
|
25
|
Hahn SH, Kim Y, Penaflor B, Bak J, Han H, Hong J, Jeon Y, Jeong J, Joung M, Juhn J, Kim J, Kim H, Lee W, Woo M, Eidietis N, Ferron J, Humphreys D, Hyatt A, Johnson R, Piglowski D, Walker M, Welander A, Mueller D, Milne P. Progress and plan of KSTAR plasma control system upgrade. Fusion Engineering and Design 2016. [DOI: 10.1016/j.fusengdes.2016.05.018] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
Steiner C, Steurer MP, Mueller D, Zueger M, Dullenkopf A. Midazolam plasma concentration after anesthesia premedication in clinical routine - an observational study : Midazolam plasma concentration after anesthesia premedication. BMC Anesthesiol 2016; 16:105. [PMID: 27776488 PMCID: PMC5078941 DOI: 10.1186/s12871-016-0262-6] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Accepted: 10/06/2016] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Midazolam is commonly used as a pre-anesthesia anxiolytic. It`s elimination may not be fast enough for short procedures. In orally premedicated patients we obtained midazolam plasma concentrations at the end of surgical procedures and compared those to concentrations at anesthesia induction. METHODS The study was conducted prospectively with consent of the local ethics committee (Ethikkomission Kanton Thurgau, Switzerland) and carried out with written informed consent of each patient. Female patients aged 20 to 60 years undergoing elective procedures with general anesthesia were included, and were divided in two groups according to the planned surgical time: group S (<30 min) and group L (90-120 min), respectively. All patients received 7.5 mg Midazolam po as premedication. Blood samples were drawn at anesthesia induction, and at the end of surgery. Data were compared with t-test (independent samples; significance level p <0.05). RESULTS Twenty-five patients per group were included. Four patients were excluded from analysis, since midazolam was not detectable in any samples. Time of premedication to the 1st blood sample was not statistically different between groups, neither were Midazolam plasma levels at this time point (p = 0.94). None of the patients from group L (n = 24), but five patients in group S (n = 22) did have a higher plasma level of Midazolam at the end of the case compared to the beginning. CONCLUSIONS The elimination half-life of oral Midazolam can lead to higher plasma levels at the end of a short procedure compared to those at induction of anesthesia. TRIAL REGISTRATION German Clinical Trials Register (Deutsches Register Klinischer Studien), DRKS00005429 ; date of registration 3rd January 2014.
Collapse
Affiliation(s)
- C Steiner
- Department of Anesthesia and Intensive Care, Kantonsspital Frauenfeld, Postfach Pfaffenholzstr. 4, 8501, Zurich, Switzerland
| | - M P Steurer
- Department of Anesthesia and Perioperative Care, University of California, San Francisco, USA
| | - D Mueller
- Institute of Clinical Chemistry, University Hospital of Zurich, Zurich, Switzerland
| | - M Zueger
- Department of Laboratory Medicine, Spital Thurgau, Frauenfeld, Switzerland
| | - A Dullenkopf
- Department of Anesthesia and Intensive Care, Kantonsspital Frauenfeld, Postfach Pfaffenholzstr. 4, 8501, Zurich, Switzerland.
| |
Collapse
|
27
|
Mueller D, Krug S, Majumder M, Rinke A, Gress TM. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors. BMC Cancer 2016; 16:645. [PMID: 27538897 PMCID: PMC4989525 DOI: 10.1186/s12885-016-2642-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2016] [Accepted: 07/28/2016] [Indexed: 01/06/2023] Open
Abstract
Background Streptozocin (STZ) based chemotherapy is recommended for patients with metastatic pancreatic neuroendocrine tumors (pNET). Temozolomide as mono- or combination therapy has been suggested to be a promising alternative. However, the treatment is costly and not approved for the treatment of pNETs. Dacarbazine (DTIC) shares the active metabolite with temozolomide and is broadly available at a low cost. The aim of this study was a retrospective evaluation of the efficacy and tolerability of a lower dose DTIC-regimen in patients with progressive advanced NETs. Methods We retrospectively analyzed 75 patients with NETs predominantly of pancreatic origin treated at our center between 1998 and 2013. 650 mg/m2 of DTIC were administered intravenously over 60 min every 4 weeks. Morphological response was assessed according to RECIST1.1 criteria. The median progression free survival (PFS) was calculated using Kaplan-Meier and Cox regression methods, respectively. Univariate analyses of possible prognostic markers were performed. Results The objective response rate (ORR) was 27 % for the entire cohort and 32 % in 50 pNET patients, respectively. Stable disease (SD) was documented in 29 patients (39 %). Median PFS (mPFS) in patients receiving DTIC was 7 months (3.9–10; 95 % confidence interval). Radiological and biochemical response were the only significant prognostic markers for longer PFS in univariate analysis. Treatment was well tolerated. Nausea was the most common side effect (31 %), only one case (1.3 %) of grade 3 toxicity (vomiting) occurred. Conclusion Low dose DTIC chemotherapy is an effective and well-tolerated treatment option in patients with progressive well differentiated neuroendocrine neoplasms, especially of pancreatic origin. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2642-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Daniela Mueller
- Department of Gastroenterology, University Hospital Marburg, Baldinger Strasse, D35043, Marburg, Germany
| | - Sebastian Krug
- Department of Gastroenterology, University of Halle, Ernst-Grube-Straße 40, D 06120, Halle, Germany
| | - Moushumee Majumder
- Department of Gastroenterology, University Hospital Marburg, Baldinger Strasse, D35043, Marburg, Germany
| | - Anja Rinke
- Department of Gastroenterology, University Hospital Marburg, Baldinger Strasse, D35043, Marburg, Germany.
| | - Thomas Matthias Gress
- Department of Gastroenterology, University Hospital Marburg, Baldinger Strasse, D35043, Marburg, Germany
| |
Collapse
|
28
|
Abstract
We present a series of seven migraine patients with typical features of a migraine attack without aura, but atypical pain localization in the face in one or both of the lower two distributions of the trigeminal nerve (V2 and V3). All of them responded well to triptans. Three patients responded to preventive treatment for migraine with β-blockers ( n = 2) or valproic acid ( n = 1). These cases underline the heterogenic clinical presentation of migraine, which is sometimes difficult to diagnose even for headache specialists, and broaden the pathophysiological understanding of trigeminal nociceptive processing in migraine in the light of neuronal plasticity.
Collapse
Affiliation(s)
- M Obermann
- Department of Neurology, University of Duisburg-Essen, Essen, Germany.
| | | | | | | | | | | |
Collapse
|
29
|
Weingärtner V, Dargatz N, Weber C, Mueller D, Stock S, Voltz R, Gaertner J. Patient reported outcomes in randomized controlled cancer trials in advanced disease: a structured literature review. Expert Rev Clin Pharmacol 2016; 9:821-9. [PMID: 26959869 DOI: 10.1586/17512433.2016.1164595] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
INTRODUCTION In advanced cancer quality of life (QoL) is the most important goal of care. It is measured by patient-reported-outcomes (PRO). This structured review evaluated how randomized controlled trials (RCTs) on anti-cancer therapy in advanced cancer reported PRO. METHODS Search was performed in MEDLINE via PubMed for RCTs with median patient survival of ≤2 years. Reporting was rated with the Consolidated Standards of Reporting Trials (CONSORT) PRO extension. RESULTS Of 370 retrieved publications, 117 were eligible, but only 30/117 (26%) reported PRO. QoL was most frequently measured (29/30). On average, 4.4 (SD 2.5) of the 14 CONSORT items were met. CONCLUSION PRO are insufficiently reported in advanced cancer trials. Yet, this is paramount to enable an informed and patient-oriented decision making process.
Collapse
Affiliation(s)
- V Weingärtner
- a Department of Palliative Medicine, Clinical Trials Unit and Center for Integrated Oncology (CIO) Cologne/Bonn , University Hospital of Cologne , Cologne , Germany
| | - N Dargatz
- a Department of Palliative Medicine, Clinical Trials Unit and Center for Integrated Oncology (CIO) Cologne/Bonn , University Hospital of Cologne , Cologne , Germany
| | - C Weber
- b Institute of Health Economics and Clinical Epidemiology (IGKE) , University Hospital of Cologne , Cologne , Germany
| | - D Mueller
- b Institute of Health Economics and Clinical Epidemiology (IGKE) , University Hospital of Cologne , Cologne , Germany
| | - S Stock
- b Institute of Health Economics and Clinical Epidemiology (IGKE) , University Hospital of Cologne , Cologne , Germany
| | - R Voltz
- a Department of Palliative Medicine, Clinical Trials Unit and Center for Integrated Oncology (CIO) Cologne/Bonn , University Hospital of Cologne , Cologne , Germany
| | - J Gaertner
- a Department of Palliative Medicine, Clinical Trials Unit and Center for Integrated Oncology (CIO) Cologne/Bonn , University Hospital of Cologne , Cologne , Germany.,c Department of Palliative Care , University Hospital Freiburg , Freiburg , Germany.,d Competence Center Palliative Care Baden-Württemberg , University Medical Center Freiburg , Freiburg , Baden-Württemberg , Germany
| |
Collapse
|
30
|
Kurrat A, Diel P, Blei T, Kluxen F, Mueller D, Pichotta M, Soukup S, Kulling S, Oden C. Abstract P3-09-03: Combined effects of soy isoflavones and a high fat diet on the mammary gland in an animal model of diet-induced obesity. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-09-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Scope: Obesity is a major risk factor for the development of breast cancer whereas isoflavone (ISO) exposure is discussed to reduce this risk. Aim of this study was to investigate effects of dietary soy ISO intake on proliferation and estrogenicity of ISO in the mammary gland of obese female Wistar rats.
Methods: Female Wistar rats (5 – 7 rats / group) grew up on low fat ISO-depleted diet (LF IDD) or ISO-rich diet enriched with a soy based commercial extract (LF IRD; ISO: 467 mg / kg diet). Starting postnatal day 83, ovariectomized (OVX) and intact animals received high fat diet for 12 weeks to induce obesity in the absence (HF IDD) or presence of ISO (HF IRD, ISO: 431 mg / kg diet). A special diet switch group (HF IRD switch OVX), grew up on LF IDD but switched to HF IRD after ovariectomy. This mimics the short term exposure to ISO in postmenopausal Western women who take ISO supplements. Two groups receiving LF diet either with or without ISO (LF IRD, LF IDD) lifelong served as control. From ablactation until the end of the experiment body weight and food consumption were monitored twice a week. After 12 weeks of HF diet animals were sacrificed. Body weight, visceral fat mass, and serum leptin were measured, and breast tissue was excised. Protein expression of proliferating cell nuclear antigen (PCNA) and progesterone receptor (PR) in breast tissue was analyzed by both immunohistochemistry (IHC) and Western Blot as markers for proliferation and estrogenicity of ISO, respectively.
Results: Analysis of ISO plasma levels revealed 1400 nM in LF IRD group and
300 – 700 nM in HF IRD groups. HF diet increased body weight, visceral fat mass and serum leptin levels compared to LF diet. In the mammary gland HF increased expression of proliferation marker PCNA and PR as compared to LF groups. Lifelong but not short term (HF IRD switch OVX) ISO exposure reduced body weight, visceral fat mass and leptin levels in HF OVX rats. In the mammary gland lifelong ISO exposure reduced PCNA expression in both LF and HF intact animals whereas in HF OVX animals lifelong ISO exposure increased PCNA expression compared to short term ISO exposure. PR expression increased in HF IRD OVX compared to HF IDD OVX.
Conclusion: The ISO plasma levels of the rats are comparable to the average ISO plasma levels as found in Asian population. Our results show that lifelong ISO intake reduces the risk to develop obesity in female rats. In the mammary gland lifelong ISO exposure decreases cell proliferation and shows estrogenicity by increasing PR expression. Effects of short term ISO exposure are less strong compared to lifelong ISO exposure. This supports the hypothesis that only lifelong but not short term ISO exposure can reduce the risk to develop breast cancer.
Citation Format: Kurrat A, Diel P, Blei T, Kluxen F, Mueller D, Pichotta M, Soukup S, Kulling S, Oden C. Combined effects of soy isoflavones and a high fat diet on the mammary gland in an animal model of diet-induced obesity. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-09-03.
Collapse
Affiliation(s)
- A Kurrat
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - P Diel
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - T Blei
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - F Kluxen
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - D Mueller
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - M Pichotta
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - S Soukup
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - S Kulling
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| | - C Oden
- Institute of Cardiovascular Research and Sports Medicine, German Sports University Cologne, Cologne, Germany; Max Rubner-Institut, Karlsruhe, Germany, Karlsruhe, Germany; Clinic for Cattle, Endocrinology, University of Veterinary Medicine, Hannover, Germany
| |
Collapse
|
31
|
Raman R, Jarboe TR, Menard JE, Ono M, Taylor G, Nelson BA, Mueller D, Brown T. Simplifying the ST and AT Concepts. J Fusion Energ 2015. [DOI: 10.1007/s10894-015-0040-3] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
32
|
Chang DH, Hiss S, Mueller D, Hellmich M, Borggrefe J, Bunck AC, Maintz D, Hackenbroch M. Radiation Dose Reduction in Computed Tomography-Guided Lung Interventions using an Iterative Reconstruction Technique. ROFO-FORTSCHR RONTG 2015; 187:906-14. [PMID: 26085175 DOI: 10.1055/s-0035-1553125] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
PURPOSE To compare the radiation doses and image qualities of computed tomography (CT)-guided interventions using a standard-dose CT (SDCT) protocol with filtered back projection and a low-dose CT (LDCT) protocol with both filtered back projection and iterative reconstruction. MATERIALS AND METHODS Image quality and radiation doses (dose-length product and CT dose index) were retrospectively reviewed for 130 patients who underwent CT-guided lung interventions. SDCT at 120 kVp and automatic mA modulation and LDCT at 100 kVp and a fixed exposure were each performed for 65 patients. Image quality was objectively evaluated as the contrast-to-noise ratio and subjectively by two radiologists for noise impression, sharpness, artifacts and diagnostic acceptability on a four-point scale. RESULTS The groups did not significantly differ in terms of diagnostic acceptability and complication rate. LDCT yielded a median 68.6% reduction in the radiation dose relative to SDCT. In the LDCT group, iterative reconstruction was superior to filtered back projection in terms of noise reduction and subjective image quality. The groups did not differ in terms of beam hardening artifacts. CONCLUSION LDCT was feasible for all procedures and yielded a more than two-thirds reduction in radiation exposure while maintaining overall diagnostic acceptability, safety and precision. The iterative reconstruction algorithm is preferable according to the objective and subjective image quality analyses. KEY POINTS Implementation of a low-dose computed tomography (LDCT) protocol for lung interventions is feasible and safe. LDCT protocols yield a significant reduction (more than 2/3) in radiation exposure. Iterative reconstruction algorithms considerably improve the image quality in LDCT protocols.
Collapse
Affiliation(s)
- D H Chang
- Department of Radiology, University Hospital of Cologne, Germany
| | - S Hiss
- Department of Radiology, University Hospital of Cologne, Germany
| | - D Mueller
- Clinical Science, Clinical Science Philips Healthcare GmbH, Munich, Germany
| | - M Hellmich
- Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Germany
| | - J Borggrefe
- Department of Radiology, University Hospital of Cologne, Germany
| | - A C Bunck
- Department of Radiology, University Hospital of Cologne, Germany
| | - D Maintz
- Department of Radiology, University Hospital of Cologne, Germany
| | - M Hackenbroch
- Department of Radiology, University Hospital of Cologne, Germany
| |
Collapse
|
33
|
Gerhardt SP, Erickson K, Kaita R, Lawson J, Mozulay R, Mueller D, Que W, Rahman N, Schneider H, Smalley G, Tresemer K. Magnetic diagnostics for equilibrium reconstruction and realtime plasma control in NSTX-Upgrade. Rev Sci Instrum 2014; 85:11E807. [PMID: 25430372 DOI: 10.1063/1.4889781] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
This paper describes aspects of magnetic diagnostics for realtime control in National Spherical Torus Experiment-Upgrade (NSTX-U). The sensor arrangement on the upgraded center column is described. New analog and digital circuitry for processing the plasma current Rogowski data are presented. An improved algorithm for estimating the plasma vertical velocity for feedback control is presented.
Collapse
Affiliation(s)
- S P Gerhardt
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - K Erickson
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - R Kaita
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - J Lawson
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - R Mozulay
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - D Mueller
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - W Que
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - N Rahman
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - H Schneider
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - G Smalley
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - K Tresemer
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| |
Collapse
|
34
|
Mueller D, Roquemore AL, Jaworski M, Skinner CH, Miller J, Creely A, Raman P, Ruzic D. In situ measurement of low-Z material coating thickness on high Z substrate for tokamaks. Rev Sci Instrum 2014; 85:11E821. [PMID: 25430386 DOI: 10.1063/1.4893425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Rutherford backscattering of energetic particles can be used to determine the thickness of a coating of a low-Z material over a heavier substrate. Simulations indicate that 5 MeV alpha particles from an (241)Am source can be used to measure the thickness of a Li coating on Mo tiles between 0.5 and 15 μm thick. Using a 0.1 mCi source, a thickness measurement can be accomplished in 2 h of counting. This technique could be used to measure any thin, low-Z material coating (up to 1 mg/cm(2) thick) on a high-Z substrate, such as Be on W, B on Mo, or Li on Mo. By inserting a source and detector on a moveable probe, this technique could be used to provide an in situ measurement of the thickness of Li coating on NSTX-U Mo tiles. A test stand with an alpha source and an annular solid-state detector was used to investigate the measurable range of low-Z material thicknesses on Mo tiles.
Collapse
Affiliation(s)
- D Mueller
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - A L Roquemore
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - M Jaworski
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - C H Skinner
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - J Miller
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - A Creely
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08543, USA
| | - P Raman
- Department of Nuclear, Plasma, and Radiological Engineering, Center for Plasma Material Interaction, University of Illinois, Urbana, Illinois 61801, USA
| | - D Ruzic
- Department of Nuclear, Plasma, and Radiological Engineering, Center for Plasma Material Interaction, University of Illinois, Urbana, Illinois 61801, USA
| |
Collapse
|
35
|
Scharf M, Mueller D, Koenig U, Pfestroff A, Nimphius W, Figiel J, Rinke A, Koenig A, Gress T. Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature. Pancreatology 2014; 14:542-5. [PMID: 25459566 DOI: 10.1016/j.pan.2014.07.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2014] [Revised: 07/16/2014] [Accepted: 07/18/2014] [Indexed: 12/11/2022]
Abstract
Insulinomas represent the most common functional neuroendocrine tumor of the pancreas. They are usually solitary, benign, well differentiated (G1/G2) and curable by surgery. We describe the case of a 45 year old male Caucasian with a unique malignant, metastasized pancreatic insulinoma (Ki 67 of 70%, G3). To control excessive insulin production emanating in refractory hypoglycemia and growth of the highly proliferating tumor a multimodal therapeutic approach including the consecutive use of tumor debulking surgery, chemotherapy, TACE, SIRT, PRRT as well as a drug therapy with diazoxide, somatostatin analogs and everolimus was employed. Chemotherapy with carboplatin/etoposide plus everolimus provided the longest normoglycemic period. After progress chemotherapy with dacarbazine had the most positive effect, while debulking approaches such as surgery and liver directed therapies, as well as PRRT were less efficient with only transient success.
Collapse
Affiliation(s)
- Michael Scharf
- Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany
| | - Daniela Mueller
- Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany
| | - Ute Koenig
- Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany
| | - Andreas Pfestroff
- Department of Nuclear Medicine, Philipps-University, Marburg, Germany
| | | | - Jens Figiel
- Department of Radiology, Philipps-University, Marburg, Germany
| | - Anja Rinke
- Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany
| | - Alexander Koenig
- Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany
| | - Thomas Gress
- Department of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany.
| |
Collapse
|
36
|
Sikora EJ, Allen TW, Wise KA, Bergstrom G, Bradley CA, Bond J, Brown-Rytlewski D, Chilvers M, Damicone J, DeWolf E, Dorrance A, Dufault N, Esker P, Faske TR, Giesler L, Goldberg N, Golod J, Gómez IRG, Grau C, Grybauskas A, Franc G, Hammerschmidt R, Hartman GL, Henn RA, Hershman D, Hollier C, Isakeit T, Isard S, Jacobsen B, Jardine D, Kemerait R, Koenning S, Langham M, Malvick D, Markell S, Marois JJ, Monfort S, Mueller D, Mueller J, Mulrooney R, Newman M, Osborne L, Padgett GB, Ruden BE, Rupe J, Schneider R, Schwartz H, Shaner G, Singh S, Stromberg E, Sweets L, Tenuta A, Vaiciunas S, Yang XB, Young-Kelly H, Zidek J. A Coordinated Effort to Manage Soybean Rust in North America: A Success Story in Soybean Disease Monitoring. Plant Dis 2014; 98:864-875. [PMID: 30708845 DOI: 10.1094/pdis-02-14-0121-fe] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Existing crop monitoring programs determine the incidence and distribution of plant diseases and pathogens and assess the damage caused within a crop production region. These programs have traditionally used observed or predicted disease and pathogen data and environmental information to prescribe management practices that minimize crop loss. Monitoring programs are especially important for crops with broad geographic distribution or for diseases that can cause rapid and great economic losses. Successful monitoring programs have been developed for several plant diseases, including downy mildew of cucurbits, Fusarium head blight of wheat, potato late blight, and rusts of cereal crops. A recent example of a successful disease-monitoring program for an economically important crop is the soybean rust (SBR) monitoring effort within North America. SBR, caused by the fungus Phakopsora pachyrhizi, was first identified in the continental United States in November 2004. SBR causes moderate to severe yield losses globally. The fungus produces foliar lesions on soybean (Glycine max) and other legume hosts. P. pachyrhizi diverts nutrients from the host to its own growth and reproduction. The lesions also reduce photosynthetic area. Uredinia rupture the host epidermis and diminish stomatal regulation of transpiration to cause tissue desiccation and premature defoliation. Severe soybean yield losses can occur if plants defoliate during the mid-reproductive growth stages. The rapid response to the threat of SBR in North America resulted in an unprecedented amount of information dissemination and the development of a real-time, publicly available monitoring and prediction system known as the Soybean Rust-Pest Information Platform for Extension and Education (SBR-PIPE). The objectives of this article are (i) to highlight the successful response effort to SBR in North America, and (ii) to introduce researchers to the quantity and type of data generated by SBR-PIPE. Data from this system may now be used to answer questions about the biology, ecology, and epidemiology of an important pathogen and disease of soybean.
Collapse
Affiliation(s)
- E J Sikora
- Department of Entomology and Plant Pathology, Auburn University, Auburn 36849
| | - T W Allen
- Department of Biochemistry, Molecular Biology, Entomology and Plant Pathology, Delta Research and Extension Center, Mississippi State University, Stoneville 38776
| | - K A Wise
- Department of Botany and Plant Pathology, Purdue University, West Lafayette 47907
| | - G Bergstrom
- Department of Plant Pathology and Plant-Microbe Biology, Cornell University, Ithaca 14853
| | - C A Bradley
- Department of Crop Sciences, University of Illinois, Urbana 61801
| | - J Bond
- Department of Plant, Soil, and Agricultural Systems, Southern Illinois University, Carbondale 62901
| | - D Brown-Rytlewski
- Department of Plant, Soil, and Microbial Sciences, Michigan State University, East Lansing 48824
| | - M Chilvers
- Department of Plant, Soil, and Microbial Sciences, Michigan State University, East Lansing 48824
| | - J Damicone
- Department of Entomology and Plant Pathology, Oklahoma State University, Stillwater 74078
| | - E DeWolf
- Department of Plant Pathology, Kansas State University, Manhattan 66506
| | - A Dorrance
- Department of Plant Pathology, The Ohio State University, Wooster 44691
| | - N Dufault
- Department of Plant Pathology, University of Florida, Gainesville 32611
| | - P Esker
- Escuela de Agronomia, Universidad de Costa Rica, San José, Costa Rica 10111
| | - T R Faske
- Department of Plant Pathology, University of Arkansas Lonoke Research and Extension Center, Lonoke 72086
| | - L Giesler
- Department of Plant Pathology, University of Nebraska-Lincoln, Lincoln 68508
| | - N Goldberg
- Department of Plant Sciences, New Mexico State University, Las Cruces 88003
| | - J Golod
- Department of Plant Pathology and Environmental Microbiology, Pennsylvania State University, University Park 16802
| | - I R G Gómez
- Sistema Nacional de Vigilancia Epidemiologica Fitosanitaria, Centro Nacional de Referenceia Fitosanitaria, Col. Del Carmen, Coyoacan, Mexico
| | - C Grau
- Department of Plant Pathology, University of Wisconsin, Madison 53706
| | - A Grybauskas
- Department of Plant Science and Landscape Management, University of Maryland, College Park 20742
| | | | - R Hammerschmidt
- Department of Plant, Soil, and Microbial Sciences, Michigan State University, East Lansing 48824
| | - G L Hartman
- United States Department of Agriculture/Agricultural Research Service, Urbana 61801
| | - R A Henn
- Department of Biochemistry, Molecular Biology, Entomology, and Plant Pathology, Mississippi State 39762
| | - D Hershman
- Department of Plant Pathology, University of Kentucky Research and Education Center, Princeton 42445
| | - C Hollier
- Department of Plant Pathology and Crop Physiology, Louisiana State University Agricultural Center, Baton Rouge 70803
| | - T Isakeit
- Department of Plant Pathology & Microbiology, Texas A&M University, College Station 77843
| | - S Isard
- Department of Plant Pathology and Environmental Microbiology, Pennsylvania State University, University Park 16802
| | - B Jacobsen
- Department of Plant Sciences and Plant Pathology, Montana State University, Bozeman 59717
| | - D Jardine
- Department of Plant Pathology, Kansas State University, Manhattan 66506
| | - R Kemerait
- Department of Plant Pathology, University of Georgia, Tifton 31793
| | - S Koenning
- Department of Plant Pathology, North Carolina State University, Raleigh 27695
| | - M Langham
- Department of Plant Science, South Dakota State University, Brookings 57007
| | - D Malvick
- Department of Plant Pathology, University of Minnesota, St. Paul 55108
| | - S Markell
- Department of Plant Pathology, North Dakota State University, Fargo 58108
| | - J J Marois
- Department of Plant Pathology, University of Florida, Gainesville 32611
| | - S Monfort
- Edisto Research and Education Center, Clemson University, Blackville 29817
| | - D Mueller
- Department of Plant Pathology and Microbiology, Iowa State University, Ames 50011
| | - J Mueller
- Edisto Research and Education Center, Clemson University, Blackville 29817
| | - R Mulrooney
- Department of Plant and Soil Science, University of Delaware, Newark 19716
| | - M Newman
- BASF Corporation, Jackson, TN 38301
| | | | - G B Padgett
- Department of Plant Pathology and Crop Physiology, Louisiana State University Agricultural Center, Baton Rouge 70803
| | - B E Ruden
- South Dakota Wheat Growers Association, Aberdeen 57401
| | - J Rupe
- Department of Plant Pathology, University of Arkansas, Fayetteville 72701
| | - R Schneider
- Department of Plant Pathology and Crop Physiology, Louisiana State University Agricultural Center, Baton Rouge 70803
| | - H Schwartz
- Department of Bioagricultural Sciences and Pest Management, Colorado State University, Fort Collins 80523
| | - G Shaner
- Department of Botany and Plant Pathology, Purdue University, West Lafayette 47907
| | - S Singh
- Department of Plant, Soil and Entomological Sciences, University of Idaho, Kimberly 83341
| | - E Stromberg
- Department of Plant Pathology, Physiology, and Weed Science, Virginia Polytechnic Institute and State University, Blacksburg 24061
| | - L Sweets
- Division of Plant Sciences, University of Missouri, Columbia 65211
| | - A Tenuta
- Ontario Ministry of Agriculture and Food, and Ministry of Rural Affairs, Ridgetown, Ontario, Canada, NOP2CO
| | - S Vaiciunas
- New Jersey Department of Agriculture, Trenton 08625
| | - X B Yang
- Department of Plant Pathology and Microbiology, Iowa State University, Ames 50011
| | - H Young-Kelly
- Department of Entomology and Plant Pathology, University of Tennessee West Tennessee Research and Education Center, Jackson 38301
| | - J Zidek
- ZedX Incorporated, Bellefonte, PA 16823
| |
Collapse
|
37
|
Hahn SH, Welander A, Yoon S, Bak J, Eidietis N, Han H, Humphreys D, Hyatt A, Jeon Y, Johnson R, Kim H, Kim J, Kolemen E, Mueller D, Penaflor B, Piglowski D, Shin G, Walker M, Woo M. Progress and improvement of KSTAR plasma control using model-based control simulators. Fusion Engineering and Design 2014. [DOI: 10.1016/j.fusengdes.2013.12.040] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Schmitter M, Schweiger M, Mueller D, Rues S. Effect on in vitro fracture resistance of the technique used to attach lithium disilicate ceramic veneer to zirconia frameworks. Dent Mater 2014; 30:122-30. [DOI: 10.1016/j.dental.2013.10.008] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Revised: 06/07/2013] [Accepted: 10/18/2013] [Indexed: 11/25/2022]
|
39
|
Schmitter M, Mueller D, Rues S. In vitro chipping behaviour of all-ceramic crowns with a zirconia framework and feldspathic veneering: comparison of CAD/CAM-produced veneer with manually layered veneer. J Oral Rehabil 2013; 40:519-25. [PMID: 23663118 DOI: 10.1111/joor.12061] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/18/2013] [Indexed: 12/01/2022]
Abstract
The purpose of this in vitro study was to assess the breaking load of zirconia-based crowns veneered with either CAD/CAM-produced or manually layered feldspathic ceramic. Thirty-two identical zirconia frameworks (Sirona inCoris ZI, mono L F1), 0·6 mm thick with an anatomically shaped occlusal area, were constructed (Sirona inLab 3.80). Sixteen of the crowns were then veneered by the use of CAD/CAM-fabricated feldspathic ceramic (CEREC Bloc, Sirona) and 16 by the use of hand-layered ceramic. The CAD/CAM-manufactured veneer was attached to the frameworks by the use of Panavia 2.0 (Kuraray). Half of the specimens were loaded until failure without artificial ageing; the other half of the specimens underwent thermal cycling and cyclic loading (1·2 million chewing cycles, force magnitude F(max) = 108 N) before the assessment of the ultimate load. To investigate the new technique further, finite element (FE) computations were conducted on the basis of the original geometry. Statistical assessment was made by the use of non-parametric tests. Initial breaking load was significantly higher in the hand-layered group than in the CAD/CAM group (mean: 1165·86 N versus 395·45 N). During chewing simulation, however, 87·5% (7/8) of the crowns in the hand-layered group failed, whereas no crown in the CAD/CAM group failed. The CAD/CAM-produced veneer was significantly less sensitive to ageing than the hand-layered veneer.
Collapse
Affiliation(s)
- M Schmitter
- Section for Biomaterial Research, Department of Prosthodontics, University of Heidelberg, Heidelberg, Germany
| | | | | |
Collapse
|
40
|
Smith DL, Fritz C, Watson Q, Willis DK, German TL, Phibbs A, Mueller D, Dittman JD, Saalau-Rojas E, Whitham SA. First Report of Soybean Vein Necrosis Disease Caused by Soybean vein necrosis-associated virus in Wisconsin and Iowa. Plant Dis 2013; 97:693. [PMID: 30722207 DOI: 10.1094/pdis-11-12-1096-pdn] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Several viral diseases of soybean (Glycine max) have been identified in the north-central U.S. soybean production area, which includes Wisconsin and Iowa (2). Previously, Soybean vein necrosis disease (SVND) caused by Soybean vein necrosis-associated virus was reported in Arkansas, Tennessee, and other southern states (4). In September 2012, soybean plants with symptoms similar to those reported for SVND (4) were observed in fields across Wisconsin and Iowa. Symptoms included leaf-vein and leaf chlorosis, followed by necrosis of the leaf veins and eventually necrosis of the entire leaf. Six samples with symptoms indicative of SVNaV were collected from research plots located at the West Madison Agricultural Research Station located in Madison, WI. An additional three samples were collected from three locations in central Iowa. Total RNA extracted from each sample using the Trizol Plus RNA purification kit (Invitrogen, Carlsbad, CA) was used to generate complementary DNA (cDNA) using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA) following the manufacturers' suggested protocols. The resulting cDNA was used as template in a PCR with SVNaV-specific primers, SVNaV-f1 and SVNaV-r1 (3). PCRs of two of the six Wisconsin samples and two Iowa samples were positive. Amplification products were not detected in the other five samples. The amplification products from the four strongly positive samples were purified using the Wizard SV Gel and PCR Purification Kit (Promega, Madison, WI) following the manufacturer's suggested protocol and were subjected to automated sequencing (University of Wisconsin Biotechnology Center or Iowa State University, DNA Sequencing Facilities). BLASTn (1) alignments of the 915-bp consensus sequence revealed 98% and >99% identity of the Wisconsin and Iowa samples, respectively, with the 'S' segment of the SVNaV 'TN' isolate (GenBank Accession No. GU722319.1). Samples from the same leaf tissue used above, were subjected to serological tests for SVNaV using antigen coated-indirect ELISA (3). Asymptomatic soybeans grown in the greenhouse were used as a source of leaves for negative controls. These tests confirmed the presence of SVNaV in eight symptomatic soybean leaflets collected in Wisconsin and Iowa. The asymptomatic control and one Iowa sample, which was also PCR-negative, were also negative by serological testing. Six additional samples from soybean fields in as many Wisconsin counties (Fond Du Lac, Grant, Green, Juneau, Richland, Rock) tested positive for SVNaV using specific primers that amplify the 'L' segment (4). The sequenced amplification products (297-bp) showed 99 to 100% homology to the L segment of the TN isolate (GU722317.1). To our knowledge, this is the first report of SVNaV associated with soybean and the first report of SVND in Wisconsin and Iowa. Considering that little is known about SVNaV, it is assumed that it is like other Tospoviruses and can cause significant yield loss (4). Soybean is a major cash crop for Wisconsin and Iowa, and infection by SVNaV could result in potential yield loss in years where epidemics begin early and at a high initial inoculum level. References: (1) S. F. Altschul et al. J. Mol. Biol. 215:403, 1990. (2) G. L. Hartman et al. Compendium of Soybean Diseases, 4th ed, 1999. (3) B. Khatabi et al. Eur. J. Plant Pathol. 133:783, 2012. (4) J. Zhou et al. Virus Genes 43:289, 2011.
Collapse
Affiliation(s)
- D L Smith
- Department of Plant Pathology, University of Wisconsin, Madison
| | - C Fritz
- Department of Plant Pathology, University of Wisconsin, Madison
| | - Q Watson
- Department of Plant Pathology, University of Wisconsin, Madison
| | - D K Willis
- USDA-ARS Vegetable Crops Research Unit and Department of Plant Pathology, University of Wisconsin, Madison
| | - T L German
- Department of Entomology, University of Wisconsin, Madison
| | - A Phibbs
- Wisconsin Department of Agriculture, Trade, and Consumer Protection, Madison
| | - D Mueller
- Department of Plant Pathology and Microbiology, Iowa State University, Ames
| | - J D Dittman
- Department of Plant Pathology and Microbiology, Iowa State University, Ames
| | - E Saalau-Rojas
- Department of Plant Pathology and Microbiology, Iowa State University, Ames
| | - S A Whitham
- Department of Plant Pathology and Microbiology, Iowa State University, Ames
| |
Collapse
|
41
|
Mokry T, Mueller D, Bellemann N, Klauss M, Stampfl U, Longerich T, Schirmacher P, Schemmer P, Radeleff B, Kauczor HU, Sommer CM. Leberlebendspende: Präoperative CT-Volumetrie mittels semi-automatischer Prototyp-Software im Vergleich zu intraoperativ bestimmtem Transplantatgewicht als Goldstandard. ROFO-FORTSCHR RONTG 2013. [DOI: 10.1055/s-0033-1346327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
42
|
Mueller D, Ferrão MF, Marder L, da Costa AB, de Cássia de Souza Schneider R. Fourier transform infrared spectroscopy (FTIR) and multivariate analysis for identification of different vegetable oils used in biodiesel production. Sensors (Basel) 2013; 13:4258-71. [PMID: 23539030 PMCID: PMC3673082 DOI: 10.3390/s130404258] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/30/2013] [Revised: 03/08/2013] [Accepted: 03/22/2013] [Indexed: 11/17/2022]
Abstract
The main objective of this study was to use infrared spectroscopy to identify vegetable oils used as raw material for biodiesel production and apply multivariate analysis to the data. Six different vegetable oil sources—canola, cotton, corn, palm, sunflower and soybeans—were used to produce biodiesel batches. The spectra were acquired by Fourier transform infrared spectroscopy using a universal attenuated total reflectance sensor (FTIR-UATR). For the multivariate analysis principal component analysis (PCA), hierarchical cluster analysis (HCA), interval principal component analysis (iPCA) and soft independent modeling of class analogy (SIMCA) were used. The results indicate that is possible to develop a methodology to identify vegetable oils used as raw material in the production of biodiesel by FTIR-UATR applying multivariate analysis. It was also observed that the iPCA found the best spectral range for separation of biodiesel batches using FTIR-UATR data, and with this result, the SIMCA method classified 100% of the soybean biodiesel samples.
Collapse
Affiliation(s)
- Daniela Mueller
- Programa de Pós-Graduação em Sistemas e Processos Industriais, Universidade de Santa Cruz do Sul (UNISC), Av. Independência, 2293, CEP 96815-900, Santa Cruz do Sul–RS, Brasil; E-Mails: (D.M.); (L.M.); (A.B.C.)
| | - Marco Flôres Ferrão
- Instituto de Química, Universidade Federal do Rio Grande do Sul (UFRGS), Av. Bento Gonçalves, 9500, CEP 91501-970, Porto Alegre–RS, Brasil
- Author to whom correspondence should be addressed; E-Mail: ; Tel.: +55-51-3308-6268; Fax: +55-51-3308-7304
| | - Luciano Marder
- Programa de Pós-Graduação em Sistemas e Processos Industriais, Universidade de Santa Cruz do Sul (UNISC), Av. Independência, 2293, CEP 96815-900, Santa Cruz do Sul–RS, Brasil; E-Mails: (D.M.); (L.M.); (A.B.C.)
| | - Adilson Ben da Costa
- Programa de Pós-Graduação em Sistemas e Processos Industriais, Universidade de Santa Cruz do Sul (UNISC), Av. Independência, 2293, CEP 96815-900, Santa Cruz do Sul–RS, Brasil; E-Mails: (D.M.); (L.M.); (A.B.C.)
| | - Rosana de Cássia de Souza Schneider
- Programa de Pós-Graduação em Tecnologia Ambiental, Universidade de Santa Cruz do Sul (UNISC), Av. Independência, 2293, CEP 96815-900, Santa Cruz do Sul–RS, Brasil; E-Mail:
| |
Collapse
|
43
|
Mueller D, Blei T, Soukup S, Gerhäuser C, Kulling S, Lehmann L, Vollmer G, Diel P. Effects of isoflavone exposure on the androgen sensitivity of male Wistar rats. Exp Clin Endocrinol Diabetes 2013. [DOI: 10.1055/s-0033-1336680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
44
|
Chang DH, Mueller D, Bangard C. Popliteales arterielles Entrapmentsyndrom - seltene Ursache einer thrombembolischen Unterschenkelischämie einer 14-Jährigen. ROFO-FORTSCHR RONTG 2013; 185:490-1. [DOI: 10.1055/s-0032-1330518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
45
|
Xiao B, Yuan Q, Humphreys D, Walker M, Hyatt A, Leuer J, Jackson G, Mueller D, Penaflor B, Pigrowski D, Johnson R, Welander A, Zhang R, Luo Z, Guo Y, Xing Z, Zhang Y. Recent plasma control progress on EAST. Fusion Engineering and Design 2012. [DOI: 10.1016/j.fusengdes.2012.06.013] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
46
|
Hansen N, Obermann M, Uçeyler N, Zeller D, Mueller D, Yoon MS, Reiners K, Sommer C, Katsarava Z. [Clinical application of pain-related evoked potentials]. Schmerz 2012; 26:8-15. [PMID: 22134376 DOI: 10.1007/s00482-011-1117-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
Pain-related evoked potentials (PREPs) represent a novel method for the evaluation of peripheral and central nociceptive pathways, e.g. in the diagnosis of small fiber neuropathy (SFN) or after therapeutic interventions for headache. Compared to contact heat-evoked and laser-evoked potentials, recording of PREPs is less stressful for the subjects and technically less demanding. The clinical usefulness of PREPs has been described for SFN associated with diabetes, HIV and hepatitis C infections as well as in headache and facial pain disorders. They have also been evaluated after interventional methods, such as direct current stimulation (tDCS). The article reviews and discusses the advantages and pitfalls of this technique in the context of recent clinical studies as compared to other paradigms of peripheral electrical stimulation and delineates perspectives and possible indications.
Collapse
Affiliation(s)
- N Hansen
- Neurologische Klinik, Universitätsklinikum Würzburg, Josef-Schneider-Strasse 11, Würzburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Kugel H, Allain J, Bell M, Bell R, Diallo A, Ellis R, Gerhardt S, Heim B, Jaworski M, Kaita R, Kallman J, Kaye S, LeBlanc B, Maingi R, McLean A, Menard J, Mueller D, Nygren R, Ono M, Paul S, Raman R, Roquemore A, Sabbagh S, Schneider H, Skinner C, Soukhanovskii V, Taylor C, Timberlake J, Viola M, Zakharov L. NSTX plasma operation with a Liquid Lithium Divertor. Fusion Engineering and Design 2012. [DOI: 10.1016/j.fusengdes.2011.07.010] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
48
|
Seifert-Klauss V, Fillenberg S, Schneider H, Luppa P, Mueller D, Kiechle M. Bone loss in premenopausal, perimenopausal and postmenopausal women: results of a prospective observational study over 9 years. Climacteric 2012; 15:433-40. [PMID: 22443333 DOI: 10.3109/13697137.2012.658110] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- V Seifert-Klauss
- Frauenklinik und Poliklinik der TU München, Klinikum rechts der Isar, München, Germany
| | | | | | | | | | | |
Collapse
|
49
|
Mueller OM, Schlamann M, Mueller D, Sandalcioglu IE, Forsting M, Sure U. Intracranial aneurysms: optimized diagnostic tools call for thorough interdisciplinary treatment strategies. Ther Adv Neurol Disord 2011; 4:267-79. [PMID: 22010040 DOI: 10.1177/1756285611415309] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
OBJECTIVE Intracranial aneurysms (IAs) require deliberately selected treatment strategies as they are incrementally found prior to rupture and deleterious subarachnoid haemorrhage (SAH). Multiple and recurrent aneurysms necessitate both neurointerventionalists and neurosurgeons to optimize aneurysmal occlusion in an interdisciplinary effort. The present study was conducted to condense essential strategies from a single neurovascular centre with regard to the lessons learned. METHOD Medical charts of 321 consecutive patients treated for IAs at our centre from September 2008 until December 2010 were retrospectively analysed for clinical presentation of the aneurysms, multiplicity and treatment pathways. In addition, a selective Medline search was performed. RESULTS A total of 321 patients with 492 aneurysms underwent occlusion of their symptomatic aneurysm: 132 (41.1%) individuals were treated surgically, 189 (58.2%) interventionally; 138 patients presented with a SAH, of these 44.2% were clipped and 55.8% were coiled. Aneurysms of the middle cerebral artery were primarily occluded surgically (88), whereas most of the aneurysms of the internal carotid artery and anterior communicating artery (114) were treated endovascularly. Multiple aneurysms (range 2-5 aneurysms/individual) were diagnosed in 98 patients (30.2%). During the study period 12 patients with recurrent aneurysms were allocated to another treatment modality (previously clip to coil and vice versa). CONCLUSIONS Our data show that successful interdisciplinary occlusion of IAs is based on both neurosurgical and neurointerventional therapy. In particular, multiple and recurrent aneurysms require tailored individual approaches to aneurysmal occlusion. This is achieved by a consequent interdisciplinary pondering of the optimal strategy to occlude IAs in order to prevent SAH.
Collapse
Affiliation(s)
- Oliver M Mueller
- Department of Neurosurgery, University Hospital Essen, Essen, Germany
| | | | | | | | | | | |
Collapse
|
50
|
Sidorenko I, Monetti R, Bauer J, Mueller D, Rummeny E, Eckstein F, Matsuura M, Lochmueller EM, Zysset P, Raeth C. Assessing Methods for Characterising Local and Global Structural and Biomechanical Properties of the Trabecular Bone Network. Curr Med Chem 2011; 18:3402-9. [DOI: 10.2174/092986711796504754] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2011] [Accepted: 05/12/2011] [Indexed: 11/22/2022]
|